

Curriculum Vitae

KEVIN W. GAREY, BS, PharmD, MS, FASHP, FIDSA, FCCP, BCIDP

CURRENT ACADEMIC APPOINTMENTS

University of Houston College of Pharmacy Dept. of Pharmacy Practice & Translational Research Houston, TX	Department Chair	2007-
University of Houston College of Pharmacy Houston, TX	Professor	2013-
University of Texas School of Public Health Houston, TX	Adjunct Professor	2014-
University of Houston	Robert L. Boblitt Endowed Professor in Drug Discovery	2022-

PAST ACADEMIC APPOINTMENTS

University of Illinois at Chicago College of Pharmacy Chicago, IL	Clinical Associate	1998-2001
University of Houston College of Pharmacy Houston, TX	Assistant Professor	2001-07
University of Houston College of Pharmacy Houston, TX	Associate Professor	2007-2013
University of Texas School of Public Health Houston, TX	Adjunct Associate Professor	2008-2014

EDUCATION

Dalhousie University Halifax, NS	Bachelor of Science in Pharmacy	1991-95
State University of New York at Buffalo Buffalo, NY	Doctorate of Pharmacy	1995-97
University of Texas School of Public Health Houston, TX	Master of Science in Biometry	2002-07

PROFESSIONAL TRAINING

Mary Imogene Bassett Hospital Cooperstown, NY	Pharmacy Practice Residency	1997-98
University of Illinois at Chicago Chicago, IL	Infectious Diseases Residency	1998-99
University of Illinois at Chicago Chicago, IL	Fellowship in Infectious Diseases	1999-2001

OTHER WORK EXPERIENCE

HMCS SCOTIAN Naval Reserve Station Halifax, Nova Scotia.	Naval Control of Shipping Officer	1991-94
Lawton's Drugs Halifax, Nova Scotia.	Student pharmacist	1993-94
United States Pharmacopeia Rockville, Maryland.	Summer intern	1994
Clinical Retroviral Lab University at Buffalo Buffalo, New York.	Research assistant	1995-96
Poison Control Center Children's Hospital of Buffalo Buffalo, New York.	Poison Control Specialist	1996-97
Roswell Park Cancer Institute Buffalo, New York.	Research assistant	1997

PROFESSIONAL SOCIETIES

American College of Clinical Pharmacy (ACCP)	1996-
American Society of Health System Pharmacy (ASHP)	1997-
The Society of Infectious Disease Pharmacists (SIDP)	1997-
American Society of Microbiology (ASM)	1999-
Infectious Diseases Society of America	2006-

PROFESSIONAL ACTIVITIES

<i>Society of Infectious Diseases Pharmacists (SIDP)</i>	
Member, Membership committee	1998-2000
Member, Annual meeting committee	2001
Member, Research committee	2017
Member, Fundraising committee	2017
Member, Guidelines committee	2019-20
<i>American Society of Health Systems Pharmacists (ASHP)</i>	
Member, ASHP Midyear Section of Clinical Specialists Programming Committee	2006-07
Vice-chair, ASHP Midyear Section of Clinical Specialists Programming Committee	2007-08
Chair, ASHP Midyear Section of Clinical Specialists Programming Committee	2008-09
Member, ASHP Sustained Contribution to the Medical Literature Award Committee	2008-11
Member, ASHP Midyear Educational Programming Committee	2011

Member, ASHP Foundations Literature Awards Program, Drug Therapy Award	2013
Program Leader, ASHP's Infectious Diseases Pharmacy Specialty Review Program	2017-23
Member, ASHP Foundations Literature Awards Program, Resident Research Award	2025
PharmD program Self-study Accreditation team United Arabs Emirates University, Al Ain, UAE	2016
<i>Infectious Diseases Society of America (IDSA)</i>	
Member, IDSA Clinical Practice Guidelines for <i>C. difficile</i> Infection	2012
Member, IDSA Standards and Practice Guidelines Committee (3-year term)	2016-19
Member, IDSA Concise Clinical Practice Guidelines for <i>C. difficile</i> infection	2020-21
Fellow, IDSA	2021

HONORS/AWARDS

Research Fellowship Award, University of Illinois at Chicago	2000
SIDP Pharmacists Research Award.	2000
ACCP ID-PRN Resident/Fellow Research Award	2000
Rho Chi member	2003
Who's Who in Medicine and Healthcare	2003
University of Houston College of Pharmacy Rho Chi Teacher Excellence Award	2003
University of Houston College of Pharmacy Faculty Teaching Excellence Award	2003
Finalist, University of Houston Faculty Teaching Award	2004
University of Houston College of Pharmacy Rho Chi Teacher Excellence Award	2005
University of Houston College of Pharmacy Faculty Preceptor Award	2005
Selected Best Papers in Mycology ICAAC 2006, San Francisco, CA	2006
University of Houston College of Pharmacy Faculty Research Excellence Award	2007
SIDP Impact Paper in Infectious Diseases Pharmacotherapy Award	2007
ASHP Drug Therapy Research Award	2007
Best Review Paper of 2009, <i>Journal of Hospital Infection</i>	2009
ASHP Best Practices Award in Health-System Pharmacy	2010
Fellow, American Society of Health-System Pharmacy	2012
SIDP Impact Paper in Infectious Diseases Pharmacotherapy Award	2012
University of Houston PLS Faculty Leadership Award	2013
Top 10 Papers in Mycology, ICAAC 2014, Washington, DC	2014
Rho Chi Bergy Lecture Recipient, West Virginia University Morgantown, WV	2017
IDSA Antimicrobial Stewardship Center of Excellence, Baylor St. Luke's Medical Center	2020
Board Certified Infectious Diseases Pharmacist (BCIDP)	2020
Fellow, Infectious Diseases Society of America	2020
Fellow, American College of Clinical Pharmacy	2021
ACCP Russell R. Miller Award	2022
Robert L. Boblitt Endowed Professor in Drug Discovery	2022
Peggy Lillis Foundation's 2023 Innovator Award	2023
ASHP Foundation Award for Sustained Contributions to the Literature	2023
SIDP Mentorship Award	2025

LISCENSURES / CERTIFICATES

Advanced Cardiac Life Support (ACLS)
Basic Life Support (BLS)
Pharmacy licensure Illinois
Pharmacy licensure Texas

UNIVERSITY AND HOSPITAL COMMITTEES

University of Houston College of Pharmacy Committees

Member	Student Interview Committee	2002-08
Chair	Infectious Disease Tenure Track Search Committee	2002
Member	Internet Technology Committee	2003-05
Member	Infectious Disease Fellowship Search Committee	2003
Department Representative	Faculty Advisory Council (elected position)	2003-05
Chair	Internal Medicine Tenure Track Search Committee	2004
Chair	Critical care Tenure Track Search Committee	2005-06
Chair	Faculty Advisory Committee (elected position)	2006-07
Member	Ad hoc committee review of guidelines for the promotion of non-tenure track faculty	2007
Member	Promotion and tenure committee	2007
Member	Executive council	2006-
Chair	Dept of Clinical Sciences and Administration	2007-
Chair	ACPE Self-study Chair, Standards 24-26	2010-11

St. Luke's Episcopal Hospital Committees

Member	Sternal Wound Infection Taskforce	2002-07
Member	Infections Committee	2002-
Member	Drug Use Evaluation Committee	2002-08
Member	Antibiotic subcommittee	2002-08
Member	Center for Antimicrobial Stewardship	2008-

TEACHING EXPERIENCE

Didactic

Undergraduate (BS Pharmaceutical Sciences)

Lecturer for pharmacoepidemiology (10-15 hrs/year)	2009-10
Lecturer for Drug Information (2 hrs/year)	2009-10

Professional Pharmacy program (PharmD)

Lecturer for drug therapeutics, pharmacodynamics, research methods, infectious disease elective (course coordinator), OTC agents, and literature evaluation (20-30 hrs/year)	2001-
--	-------

Graduate (MS and PhD)

Lecturer and course coordinator for pharmacoepidemiology (42 hrs/year)	2003-06
Lecturer for Pharmacoepidemiology (15-20 hours/year)	2007-11
Lecturer for Research Seminar in Pharmacy Administration (1-2 hrs/year)	2009-
Lecturer for Pharmacy Administration II (3 hrs/year)	2010-17
Coordinator and lecturer for Seminar Series in Healthcare leadership (28 hrs/year)	2010-
Lecturer for Residency Teaching Certificate Program (2 hrs/year)	2010-22
Coordinator and lecturer for Introduction to Health System Management (36 hrs/yr)	2011-12

Clinical Instructor / Experiential Training

Infectious Diseases St. Luke's Episcopal Hospital	Pharmacy student preceptor (3-5 months/year)	2002-
Infectious Diseases	Pharmacy resident preceptor (2-10 months/year)	2002-

St. Luke's Episcopal Hospital

Academia rotation	Pharmacy resident preceptor (2-6 months/year)	2009-
University of Houston College of Pharmacy		

Academia and Infectious Diseases	National University of Singapore (1-4 months/yr) Pharmacy student preceptor	2011-8
----------------------------------	--	--------

Postdoctoral fellows

Elizabeth Hirsch, PharmD		2008-10
Current position: Professor, University of Minnesota		
Dhara Shah, PharmD		2009-11
Current position: Clinical Associate Professor, University of Houston		
Cecilia Truc Tran, PharmD		2009-12
Current position: Associate Professor, Houston Methodist/ Columbia University		
Nicholas Beyda, PharmD		2010-13
Current position: Associate Professor, University of Houston		
Dana Bowers, PharmD		2011-13
Current position: Clinical Associate Professor, Washington State University, Yakima, WA		
Samuel Aitken, PharmD		2012-14
Current position: ID pharmacist, University of Michigan Medical Center, Ann Arbor, MI		
Kady Phe, PharmD		2013-15
Current position: ID pharmacist, Baylor St. Luke's Medical Center, Houston TX		
Nancy Vuong, PharmD		2014-16
Current position: ID pharmacist, MD Anderson Cancer Center Houston TX		
Eugenie Basseres, PhD		2015-19
Current position: Research Scientist, University of Houston, Houston TX		
Bradley Endres, PhD		2015-19
Current position: ID Pharmacist, Milwaukee VA, Milwaukee, WI		
Kierra Dotson, PharmD		2016-18
Current position: Clinical Assistant Professor, Xavier University, New Orleans, LA		
Anne Gonzales-Luna, PharmD		2017-19
Current position: Adjunct Assistant Professor, University of Houston, Houston TX		
Travis Carlson, PharmD		2017-19
Current position: Clinical Assistant Professor, University of Texas, Austin TX		
Josh Hendrickson, PharmD		2018-20
Current position: ID pharmacist, MD Anderson Cancer Center Houston TX		
Andrei Zidaru, PharmD		2019-21
Current position: ID pharmacist, Baylor St. Luke's Medical Center, Houston TX		
Masaad Saeed, PharmD		2019-21
Current position: Assistant Professor, Qassim University, Saudi Arabia		
Saad Fallatah, PharmD		2019-21
Current position: Clinical Assistant Professor, Taibah University, Madinah, Saudi Arabia		
Jinhee Jo, PharmD		2020-22
Current position: Adjunct Assistant Professor, University of Houston, Houston TX		
Ahmed Zaki, PharmD		2020-22
Current position: Clinical pharmacist, CHI St. Luke's Health, Woodlands TX		
Taryn Eubank, PharmD		2021-2023
Current position: Research Assistant Professor, University of Houston		
Hubert Chua, PharmD		2021-2023
Current position: Clinical Assistant Professor, St. John's University		
Nico Teran, PharmD		2021-2023
Current position: ID pharmacist, Houston Methodist, Baytown Texas		

Ricky Huynh-Phan, PharmD	Postdoctoral fellowship	2023-2025
Current position: Current fellow		

Ph.D. thesis advisor

Sumesh Kachroo, BS, MS	Ph.D. Epidemiology, UT School of Public Health	2006-08
Current position: Group Director, Real-world evidence. Johnson and Johnson		
Woranuch Saengcharoen, MS,	Ph.D. Clinical Pharmacy Prince of Songkla Univ, Thailand	2006-10
Current position: Assistant Professor, Prince of Songkla University, Thailand		
Wichai Santimaleeworagun,	Ph.D. Clinical Pharmacy, Prince of Songkla Univ, Thailand	2010-12
Current position: Assistant Professor, Silpakorn University, Thailand		
Shashank Ghantaji, MBBS	Ph.D. Public Policy, UT School of Public Health	2010-16
Current position: Medical Director Lymphoid / CAR-T Novartis		
Tasnuva Rashid, MBBS	Ph.D. Epidemiology, UT School of Public Health	2015-19
Current position: Resident Physician, University of Florida College of Medicine		
Jacob McPherson, PharmD	Ph.D., Pharmacology, UH College of Pharmacy	2021-present
MD Ekramul Karim	Ph.D., Biology, University of Houston	2022-present
ThanhPhoung Le, PharmD	Ph.D. , Pharmacology, UH College of Pharmacy	2023-present
Josef Fowler, MS	Ph.D. Pharmacology, UH College of Pharmacy	2023-present

Masters thesis advisor

Milind Rege, BS	MS Pharmacy Administration, UH College of Pharmacy (COP)	2003-4
Yu Fang Lee, BS	MS Pharmacy Administration, UH COP	2003-4
Brinda Rao, BS	MS Pharmacy Administration, UH COP	2004-5
Sumesh Kachroo, BS	MS Pharmacy Administration, UH COP	2004-5
Nandan Kumar, BS, MBA	MS Pharmacy Administration, UH COP	2004-5
Pareesh Amrutkar, BS, MBA	MS Pharmacy Administration, UH COP	2005-6
Kplola Y Elhor Gbito, MD	MPH, UT School of Public Health	2007-8
Saurabh Sethi, MBBS	MPH, UT School of Public Health	2007-8
Yashoo Yadav, MBBS	MPH, UT School of Public Health	2007-9
Vikas Kumar, MBBS	MPH, UT School of Public Health	2009-10
Philip Zweifel, PharmD	MS Pharmacy Administration, UH COP	2009-10
Linda Ho, PharmD	MS Pharmacy Administration, UH COP	2009-11
Brian Fase, PharmD	MS Pharmacy Administration, UH COP	2009-11
Becki Natalie, PharmD	MS Pharmacy Administration, UH COP	2009-11
Michael Meldrum, PharmD	MS Pharmacy Administration, UH COP	2010-12
Alex Stearns, PharmD	MS Pharmacy Administration, UH COP	2010-12
Jamie Huang, BS	MPH, UT School of Public Health	2010-12
Adidtya Lal, MBBS	MPH, UT School of Public Health	2010-12
Jennifer Pham, PharmD	MS Pharmacy Administration, UH COP	2011-13
Shreya Patel, PharmD	MS Pharmacy Administration, UH COP	2011-13
Christie Gorbach, PharmD	MS Pharmacy Administration, UH COP	2011-13
John Blee, PharmD	MS Pharmacy Administration, UH COP	2011-13
Brooke Bernhart, PharmD	MS Pharmacy Administration, UH COP	2011-13
Achsah Phillips, PharmD	MS Pharmacy Administration, UH COP	2012-14
John Blee, PharmD	MS Pharmacy Administration, UH COP	2012-14
Nelvin Daniel, PharmD	MS Pharmacy Administration, UH COP	2013-15
Brandi Hamilton, PharmD	MS Pharmacy Administration, UH COP	2014-16
Amanda Black, PharmD	MS Pharmacy Leadership and Administration, UH COP	2015-17
Josh Blackwell, PharmD	MS Pharmacy Leadership and Administration, UH COP	2015-17
Devlin Smith, PharmD	MS Pharmacy Leadership and Administration, UH COP	2016-18
Marcy Pilate, PharmD	MS Pharmacy Leadership and Administration, UH COP	2016-18
Sunny Bhakta, PharmD	MS Pharmacy Leadership and Administration, UH COP	2016-18

Alan Moyer, PharmD	MS Pharmacy Leadership and Administration, UH COP	2017-19
Megan McGugnan, PharmD	MS Pharmacy Leadership and Administration, UH COP	2017-19
Stella Kim, PharmD	MS Pharmacy Leadership and Administration, UH COP	2017-19
Arlin Ashemore, PharmD	MS Pharmacy Leadership and Administration, UH COP	2018-20
Sara Mirjamali, PharmD	MS Pharmacy Leadership and Administration, UH COP	2021-23
Yolanda Martinez, PharmD	MS Pharmacy Leadership and Administration, UH COP	2022-23
Amrita Kuman, PharmD	MS Pharmacy Leadership and Administration, UH COP	2023-24
Atra Mouser, PharmD	MS Pharmacy Leadership and Administration, UH COP	2023-24
Michael Torano, PharmD	MS Pharmacy Leadership and Administration, UH COP	2024-25

EDITORIAL BOARD APPOINTMENTS

Annals of Pharmacotherapy	2007-
Editorial Board Chair, Infectious Diseases Panel	2010-2015
Associate Editor	2015-
Antimicrobial Agents and Chemotherapy	2021-
Antibiotics	2021-

JOURNAL REVIEWER

Infection Control and Hospital Epidemiology	2002-
Annals of Pharmacotherapy	2004-
American Journal of Health System Pharmacy	2004-
Pharmacotherapy	2006-
Future Drugs	2007-
Journal of Antimicrobial Chemotherapy	2007-
BMC Infectious Diseases	2007-
American Journal of Tropical Medicine & Hygiene	2007-
Lancet	2007-
Clinical Infectious Diseases	2008-
Diagnostic Microbiology and Infectious Diseases	2009-
Digestive Diseases and Sciences	2009-
Critical Care	2009-
Archives of Internal Medicine	2009-
Scandinavian Journal of Infectious Diseases	2010-
Clinical Microbiology and Infection	2010-
Nature Reviews Gastroenterology and Hepatology	2011-
Canadian Medical Association Journal	2012-
Antimicrobial Agents and Chemotherapy	2017-
Lancet ID	2018-
Anaerobe	2018-
mBio	2018-
JAMA	2022-
N Eng J Med	2024-

PUBLICATIONS (listed in chronologic order)

Underline indicates corresponding author

Statistics:

National / International Guidelines:	2
Book chapters:	5
Original research articles:	226
<u>Case reports and reviews:</u>	<u>64</u>
Total	297

National / International Guidelines

1. LC McDonald, DN Gerding, S Johnson, JS. Bakken, KC Carroll, SE Coffin, ER Dubberke, KW Garey, CV Gould, C Kelly, Loo, JS Sammons, TJ Sandora, MH Wilcox. Clinical Practice Guidelines for *Clostridium difficile* Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis. 2018;66(7):987-94. PMID: 29462280
2. S Johnson, V Laverne, AM Skinner, AJ Gonzales-Luna, KW Garey, CP Kelly, MH Wilcox. Clinical Practice Guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 Focused Update Guidelines on Management of *Clostridioides difficile* Infection in Adults. Clin Infect Dis. 2021 Jun 24:ciab549. doi: 10.1093/cid/ciab549. PMID: 34164674

Book chapters

1. Garey KW, Rodvold KA. Drug-Food Interactions. In: Piscitelli SC, Rodvold KA, eds. Drug Interactions in Infectious Diseases. New Jersey: Humana Press Sept 2000
2. Sprandel KA, Garey KW, Rodvold KA. Drug-Food Interactions. In: Piscitelli SC, Rodvold KA, eds. Drug Interactions in Infectious Diseases 2nd Edition. New Jersey: Humana Press Aug 2005
3. Garey KW and Gerard L. Gastrointestinal infections. In: Helms R, Quan DJ, eds. Textbook of Therapeutics: Drug and Disease Management Eighth Edition. Lippincott, Williams & Wilkins, Inc. April 2006
4. Garey KW. *Clostridium difficile* infection. In: Richardson M, Chant C, Chessman KH, Finks SW, Hemstreet BA, Hume AL, et al, eds. Pharmacotherapy Self-Assessment Program, 7th ed. Infectious Diseases. Lenexa, KS: American College of Clinical Pharmacy, 2012
5. Aitken SL, Shah DN, Garey KW. Economic burden of *Clostridium difficile* infection. In: *Clostridium difficile*: New Challenges for an Old Foe. Tillotson GS, Weiss K (Eds). Future Medicine, London, UK. DOI: 10.2217/EBO.13.185 (2013). ISBN 978-1-78084-315-5

Original Research Articles

1. Garey KW, Peloquin CA, Godo PG, Nafziger AN, Amsden GW. Lack of effect of zafirlukast on the pharmacokinetics of azithromycin, clarithromycin, and 14-hydroxyclearithromycin in healthy volunteers. Antimicrob Agents Chemother 1999 May;43(5):1152-5 PMID:10223928
2. Pendland SL, Diaz-Linares M, Garey KW, Woodward JG, Ryu S, Danziger LH. Bactericidal activity and postantibiotic effect of levofloxacin against anaerobes. Antimicrob Agents Chemother 1999 Oct;43(10):2547-2549 PMID:10508042
3. Garey KW, Rubinstein I, Gotfried MH, Khan IJ, Varma S, Danziger LH. Long-term clarithromycin decreases prednisone requirements in elderly patients with prednisone-dependent asthma. Chest 2000;118:1826-7 PMID:11115481
4. Garey KW, Teichner P. Medication errors in hospitalized HIV-infected patients. Impact of a clinical pharmacist. Am J Health-Syst Pharm 2000;57:2283 PMID:11146973
5. Tornatore KM, Garey KW, Saigal N, Reed K, Murray B, Ingalls E, DiFrancesco R, Forrest A, Morse G, Venuto R. Ganciclovir pharmacokinetics and cytokine dynamics in renal transplant recipients with cytomegalovirus infection. Clin Transplant 2001 Oct;15(5):297-308 PMID:1167895
6. Cannon JP, Garey KW, Danziger LH. A concurrent and retrospective analysis of the nephrotoxicity and efficacy of lipid-based amphotericin B formulations. Pharmacotherapy 2001 Sept;21(9):1107-14 PMID:11560200
7. Garey KW, Pendland SL, Huynh VT, Bunch TH, Jensen GM, Pursell KJ. *Cunninghamella bertholletiae* infection in a bone marrow transplant patient: amphotericin lung penetration, MIC determinations, and review of the literature. Pharmacotherapy 2001 Jul;21(7):855-60 PMID:11444582

8. Garey KW, Tesoro E, Muggia V, Pasquier O, Ausman J, Rodvold KA. Cerebrospinal Fluid Concentrations of Quinupristin/Dalfopristin in a Patient with VREF Ventriculitis. *Pharmacotherapy*. 2001 Jun;21(6):748-50 PMID:11401187
9. Pendland SL, Prause JL, Neuhauser MM, Garey KW, Jung R. Comparative Killing Rates of Gatifloxacin and Ciprofloxacin: Impact of Bacterial Strain and Concentration against 14 Clinical Isolates. *Diagn Micro Infect Dis* 2002 Sep;44(1):59-61. PMID:12376032
10. Cannon JP, Fiscella R, Pattharachayakul S, Garey KW, De Alba F, Piscitelli S, Edward DP, Danziger LH. Comparative toxicity and concentrations of intravitreal amphotericin B formulations in a rabbit model. *Invest Ophthalmol Vis Sci* 2003 May;44(5):2112-7 PMID:12714650
11. Garey KW, Alwani A, Danziger LH, Rubinstein, I. Tissue reparatory effects of macrolide antibiotics in chronic inflammatory sinopulmonary diseases. *Chest* 2003;123:261-5 PMID:12527628
12. MH Gotfried, R Jung, CR. Messick, I Rubinstein, KW. Garey, KA. Rodvold, LH. Danziger. Effects of six-week clarithromycin therapy in subjects with corticosteroid-dependent asthma. *Current Therapeutic Research* 2004;65(1):1-12
13. KW Garey, MM Neuhauser, RA Robbins, LH Danziger, I Rubinstein. Markers of Inflammation In Exhaled Breath Condensate Of Young Healthy Smokers. *Chest* 2004;125:22-26 PMID: 14718416
14. MM Neuhauser, D Wiley, L Simpson, KW Garey. Professional Activities and Characteristics of Immunization Certified Pharmacists in Texas. *Ann Pharmacother* 2004;38(2):226-31. PMID:14742755
15. KW Garey, ML Johle, K Behrman, MM Neuhauser. Economic Implications of Unused Medications in Houston, Texas. *Ann Pharmacother* 2004 Jul;38(7):1165-8. PMID:15138296
16. KJ Suda, KW Garey, LH Danziger. Treatment Failures Secondary to Drug Interactions with Divalent Cations and Fluoroquinolone. *Pharm World Sci* 2005;27(2):81-2. PMID;15999916
17. S Kachroo, T Dao, F Zabaneh, M Reiter, M LaRocco, LO Gentry, and KW Garey. Tolerance of Vancomycin for Surgical Prophylaxis in Patients Undergoing Cardiac Surgery and Incidence of Vancomycin-resistant Enterococcus Colonization. *Ann Pharmacother* 2006;40(3):381-5 PMID: 16478809
18. Jiang ZD, DuPont HL, Garey K, Price M, Graham G, Okhuysen P, Dao-Tran T, LaRocco M. A Common Polymorphism in the Interleukin 8 Gene Promoter is Associated with *Clostridium difficile* Diarrhea. *Am J Gastroenterol* 2006;101:1-5 PMID: 16573784
19. KW Garey, MM Neuhauser, DT Bearden, JP Cannon, RE Lewis, LO Gentry, and DP Kontoyiannis. Evaluation of Antifungal Usage in the Surgical Intensive Care Unit: A multi-institutional study. *Mycoses* 2006;49:226-31 PMID: 16681815
20. KW Garey, G Graham, L Gerard, T Dao, ZD Jiang, M Price, and HL DuPont. Prevalence of Diarrhea at a University Hospital and Association with Modifiable Risk Factors. *Ann Pharmacother* 2006;40:1030-34 PMID: 16684806
21. KW Garey, M Rege, MP Pai, DE. Mingo, KJ Suda, RS Turpin, and DT Bearden. Time until initiation of fluconazole therapy impacts mortality in patients with candidemia: A multi-institutional study. *Clin Infect Dis* 2006;43 (1 July):25-31 PMID: 16758414
22. VH Tam, S Adams, MT LaRocco, LN Gerard, LO Gentry, KW Garey. An Integrated Pharmacoeconomic Approach for Antimicrobial Formulary Decision Making. *Amer J Health Syst Pharm* 2006 Apr 15;63(8):735-9 PMID: 16595813
23. GS Itokazu, DN Schwartz, KW Garey, KA. Rodvold, LH. Danziger, RA Weinstein. Antimicrobial Control Programs – How Well Are They Working? *Amer J Health Syst Pharm* 2006;63:2504-8 PMID:17158699
24. KW Garey, T Dao, H Chen, P Amrutkar, N Kumar, M Reiter, LO Gentry. Timing of Vancomycin Prophylaxis for Patients Undergoing Cardiac Surgery and the Risk of Surgical Site Infections. *J Antimicrob Chemother* 2006;58:645-650 PMID: 16807254

25. DO Maclayton, KJ Suda, KA Coval, TJ Gladney, CB York, KW Garey. Relationship between vancomycin MIC and risk factors, costs, and outcomes in hemodialysis patients with methicillin-resistant *Staphylococcus aureus* bacteremia. Clin Ther 2006;28:1208-16 PMID: 16982298
26. Bridges JD, Nettle CB, Dugirrala VJ, Suda KJ, and Garey KW. Low-dose granisetron for the prevention of post-operative nausea and vomiting. J Applied Res 2006;6(3):223-9
27. KW Garey, N. Kumar, T Dao, VH Tam, LO Gentry. Risk Factors for Postoperative Sternal Wound Infections due to Gram-negative Bacterial Pathogens in Cardiac Surgery Patients. J Chemother 2006;18:402-8 PMID: 17024796
28. PP Amrutkar, MD Rege, H Chen, MT LaRocco, LO Gentry, and KW Garey. Comparison of risk factors for candidemia vs. bacteremia in hospitalized patients. Infection 2006;34(6):322-7 PMID: 17180586
29. MP Pai, RS Turpin, and KW Garey. Association of Fluconazole AUC/MIC and Dose/MIC Ratios with mortality in non-neutropenic patients with candidemia. Antimicrob Agents Chemother 2007;51(1):35-9 PMID: 17101684
30. MF Price T Dao-Tran, MT, KW Garey, G Graham, LO Gentry, HL DuPont. Epidemiology and incidence of *Clostridium difficile*-associated diarrhea diagnosed upon admission to a university hospital. J Hosp Infect 2007;65(1):42-6 PMID: 17145108
31. VH Tam, AN Schilling, MT LaRocco, LO Gentry, K Lolans, JP Quinn, KW Garey. Prevalence of AmpC over-expression in bloodstream isolates of *Pseudomonas aeruginosa*. Clinical Microbiology and Infection 2007 Mar;13(4):413-8 PMID: 17359326
32. H Chen, KJ Suda, RS Turpin, MP Pai, DT Bearden and KW Garey. High vs. low-dose fluconazole therapy for treatment of invasive candidiasis among high-risk patients in the intensive care unit: A cost-effectiveness analysis. Curr Med Res Opin 2007;23(5):1057-65 PMID: 17519072
33. KW Garey, MP Pai, KJ Suda, RS. Turpin, MD. Rege, DE. Mingo, DT Bearden. Inadequacy of fluconazole dosing in patients with candidemia based on Infectious Diseases Society of America (IDSA) guidelines. Pharmacoepi Drug Safety 2007;16(8):919-27 PMID: 17286303
34. KW Garey, RS Turpin, DT Bearden, MP Pai and KJ Suda. Economic analysis of inadequate fluconazole therapy in non-neutropenic patients with candidemia: A multi-institutional study. International Journal of Antimicrobial Agents 2007;29(5):557-62 PMID: 17341444
35. Loughlin SM, Mortazavi A, Garey KW, Rice GK, Birthcher KK. Pharmacist-managed vaccination program increased influenza vaccination rates in cardiovascular patients enrolled in a secondary prevention lipid clinic. Pharmacotherapy 2007;27(5):729-33 PMID: 17461708
36. Jiang ZD, Garey KW, Price M, Graham G, Okhuysen P, Dao-Tran T, LaRocco M, DuPont HL. Association of IL-8 Polymorphism and IgG Antitoxin A in Patients with *Clostridium difficile* Diarrhea. Clinical Gastroenterology and Hepatology 2007 5(8):964-8 PMID: 17618838
37. VH Tam, K Chang, MT LaRocco, AN Schilling, SK McCauley, K Poole, KW Garey. Prevalence and mechanisms of carbapenem resistance in bloodstream isolates of *Pseudomonas aeruginosa*. Diag Micro Infect Dis 2007;58:309-14 PMID: 17617302
38. KW Garey, D Lai, TK Dao-Tran, LO Gentry, LY Hwang, BR Davis. Vancomycin compared to cefuroxime for surgical prophylaxis in patients undergoing cardiac surgery: An interrupted time series analysis. Antimicrob Agents Chemother 2008;52(2):446-517 PMID: 18025116
39. KW Garey, ZD Jiang, Y Yadav, B Mullins, K Wong, HL DuPont. Peripartum *Clostridium difficile* Infection. Case Series and Review of the Literature. Amer J Obstet Gynecol 2008;199(4):332-7 PMID: 18639213
40. VH Tam, EA Gamez, J Weston, LN Gerard, MT LaRocco, JP Caerio, LO Gentry, KW Garey. Outcomes of *Pseudomonas aeruginosa* bacteremia with reduced susceptibility to piperacillin-tazobactam: implication on the appropriateness of resistance breakpoint. Clin Infect Dis 2008;46:862-7 PMID: 18279040

41. KW Garey, P Amrutkar, TK Dao-Tran, CP Frost, H Chen, EJ Essien, and LO Gentry. Economic Benefit of Appropriate Antibiotic Timing in Patients Undergoing Cardiovascular Surgery. *Pharmacother* 2008;28:699-706 PMID: 18503397
42. KW Garey, TK Dao-Tran, ZD Jiang, MP Price, LO Gentry, HL DuPont. A clinical risk index for *Clostridium difficile* infection in hospitalized patients receiving broad-spectrum antibiotics. *J Hosp Infect* 2008;70:142-7 PMID: 18723249
43. KW Garey, MV Martorell, QP Vo, VH Tam. Killing Activity of Piperacillin and Rifampin Combination Therapy against Biofilm-embedded *Pseudomonas aeruginosa*. *J Chemother* 2008;20:652-4 PMID: 19028631
44. KW Garey, S Sethi, Y Yadav, HL DuPont. Meta-analysis to assess risk factors for recurrent *Clostridium difficile* infection. *J Hosp Infect* 2008;70:298-304 PMID: 18951661
45. KW Garey, QP Vo, MT LaRocco, LO Gentry, VH Tam. Prevalence and epidemiology of type III secretion protein exoenzymes from bloodstream isolates of patients with *Pseudomonas aeruginosa* bacteremia. *J Chemother* 2008;20(6):714-20 PMID: 19129069
46. KW Garey, QP Vo, RE Lewis, W Saengcharoen, MT LaRocco, VH Tam. Increased bacterial adherence and biomass in *Pseudomonas aeruginosa* bacteria exposed to clarithromycin. *Diag Micro Infect Dis* 2009;63(1):81-6 PMID: 18990530
47. VH Tam, KT Chang, AN Schilling, MT LaRocco, LO Gentry, KW Garey. Impact of AmpC over-expression on outcomes of patients with *Pseudomonas aeruginosa* bacteremia. *Diag Micro Infect Dis* 2009 Mar;63(3):279-85 PMID: 19135330
48. Y Yadav, KW Garey, TK Dao-Tran, V Kaila, KY Elhor Gbitto, and H. DuPont. An Automated System to Identify *Clostridium difficile* Infection Among Hospitalized Patients. *J Hosp Infect* 2009;72:337-41 PMID: 19596490
49. KW Garey, ZD Jiang, A Bellard, and HL DuPont. Rifaximin in Treatment of Recurrent *Clostridium difficile*-Associated Diarrhea, An Uncontrolled Pilot Study. *J Clin Gastroenterol* 2009;43(1):91-3 PMID: 18385603
50. M Salazar, KW Garey, ZD Jiang, TK Dao-Tran, HL DuPont. Changing *Clostridium difficile* Infection Testing and Treatment Trends at a Large Tertiary Care Teaching Hospital. *Pharm World Sci* 2009;31(5):565-71 PMID: 19657721
51. M Salazar, L Baskin, KW Garey, and HL DuPont. *Clostridium difficile*-related death rates in Texas 1999-2005. *J Infect* 2009;59(5):303-7 PMID: 19735673
52. VH Tam, KT Chang, K Abdelraouf, CG Brioso, M Ameka, LA McCaskey, JS Weston, JP Caeiro, KW Garey. Prevalence, mechanism and susceptibility of multidrug resistant bloodstream isolates of *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother* 2010 Mar;54(3):1160-4 PMID: 20086165
53. Jiang ZD, DuPont HL, LaRocco M, Garey KW. In vitro susceptibility of *Clostridium difficile* to rifaximin and rifampin in 359 consecutive isolates at a university hospital in Houston, Texas. *J Clin Pathol* 2010;63:355-58 PMID: 20354207
54. Tam VH, Rogers CA, Chang KT, Weston JS, Caeiro JP, Garey KW. Impact of Multidrug Resistant *Pseudomonas aeruginosa* Bacteremia on Patient Outcomes. *Antimicrob Agents Chemother* 2010;5:3717-22 PMID: 20585122
55. P Bhagunde, KT Chang, R Singh, V Singh, KW Garey, M Nikolaou, VH Tam. Mathematical modeling to characterize the inoculum effect. *Antimicrob Agents Chemother* 2010;54(11):4739-43 PMID: 20805390
56. KW Garey, ZD Jiang, S Ghantaji, VH Tam, V Arora, and HL DuPont. A Common Polymorphism in the Interleukin-8 Gene Promoter is Associated with Increased Risk for Recurrent *Clostridium difficile* Infection. *Clin Infect Dis* 2010;51(12):1406-1410 PMID: 21058913

57. S Sethi, KW Garey, V Arora, S Ghantaji, P Rowan, M Smolensky, HL DuPont. Increased rate of irritable bowel syndrome and functional gastrointestinal disorders after *Clostridium difficile* Infection. J Hosp Infect 2011;77:172-3 PMID 21190754
58. K Halton, V Arora, V Singh, SS Ghantaji, D Shah, and KW Garey. Bacterial colonization on writing pens touched by healthcare professionals and hospitalized patients with and without cleaning the pen with alcohol based hand sanitizing agent. Clin Micro Infect 2011;17(6):868-9. PMID: 21463395
59. Santimaleeworagun W, Wongpoowarak P, Chayakul P, Pattharachayakul S, Tansakul P, Garey KW. Clinical outcomes of patients infected with carbapenem-resistant *Acinetobacter baumannii* treated with single or combination antibiotic therapy. J Med Assoc Thai. 2011 Jul;94(7):863-70 PMID: 21774295
60. W Santimaleeworagun, P Wongpoowarak, P Chayakul, S Pattharachayakul, P Tansakul, KW Garey. *In vitro* activity of colistin or sulbactam in combination with fosfomycin or imipenem against clinical isolates of carbapenem-resistant *Acinetobacter baumannii* producing OXA-23 carbapenemases. Southeast Asian J Trop Med Public Health 2011;42(4):890-900 PMID: 22299471
61. V Arora, S Kachroo, SS Ghantaji, HL DuPont, and KW Garey. High Horn's Index predicts poor outcomes in patients with *Clostridium difficile* infection. J Hosp Infect 2011;79:23-26 PMID: 21700363
62. DN Shah, R Yau, J Weston, TM Lasco, M Salazar, HR Palmer, KW Garey. Evaluation of antifungal therapy in patients with candidemia based on susceptibility testing results: Implications for antimicrobial stewardship programs. J Antimicrob Chemother 2011;Sep;66(9):2146-51 PMID: 21700622
63. KW Garey, S Ghantaji, DN Shah, M Habib, V Arora, ZD Jiang, and HL DuPont. A randomized double-blind placebo-controlled pilot study to assess the effect of rifaximin to prevent recurrent diarrhea in patients with *Clostridium difficile* infection. J Antimicrob Chemother 2011;66(12):2850-5 PMID: 21948965
64. F Le, V Arora, DN Shah, M Salazar, HR Palmer, KW Garey. A real-world evaluation of oral vancomycin for severe *Clostridium difficile* infection: Implications for antibiotic stewardship programs. Pharmacother 2012;32(2):129-134 PMID: 22392421
65. AL Mora, M Salazar, JP Caeiro, C Frost, Y Yadav, HL DuPont, KW Garey. Moderate to High Use of Opioid Analgesics are Associated with an Increased Risk of *Clostridium difficile* Infection. Amer J Med Sci 2012;343(4):277-90 PMID:21934595
66. Crutchley RD, Gathe JC, Mayberry C, Trieu A, Abughosh S, Garey K. Risk factors for vitamin D deficiency in HIV infected patients in South Central United States. AIDS Res Hum Retroviruses. 2012;28:454-9 PMID: 21878055
67. DN Shah, R Yau, TM Lasco, J Weston, M Salazar, HR Palmer, KW Garey. Impact of prior inappropriate fluconazole dosing on isolation of fluconazole non-susceptible *Candida* species in hospitalized patients with candidemia. Antimicrob Agents Chemother 2012;56(6):3239-43 PMID: 22411611
68. Tran TT, Palmer HP, Weston J, Hirsch EB, Shah DN, Cottreau J, Tam VH, Garey KW. Evaluation of a daptomycin dose optimization protocol: A Potential Policy for Antibiotic Stewardship Programs. Amer J Health-Syst Pharm 2012;69:979-84 PMID: 22610031
69. V Singh, V Arora, MJ Alam, and KW Garey. Inhibition of biofilm formation by esomeprazole in *Pseudomonas aeruginosa* and *Staphylococcus aureus*. Antimicrob Agents Chemother 2012;56(8):4360-4 PMID: 22664967
70. L Haines, K Putney, D Varkey, E Pitman, RR Aparasu, C Frost, KW Garey. Outcomes associated with a pilot involving aspects of a patient-centered pharmacy practice model. Amer J Health-Syst Pharm 2012;69(21):1860-1 PMID: 23111668

71. Natali BJ, Varkey AC, KW Garey, and M Liebl. Impact of a real-time, dynamic, pharmacotherapy alerting system to provide feedback to pharmacists during order verification in an acute care setting. *Amer J Health Syst Pharm* 2013;70(1):48-52 PMID: 23261900
72. Beyda ND, Chuang SH, Alam MJ, Shah, DN, Ng TM, McCaskey L, KW Garey. Treatment of *Candida famata* bloodstream infections: Case Series and Review of Literature. *J Antimicrob Chemother* 2013;68(2):438-43 PMID: 23085777
73. DN Shah, NS Bhatt, JK Welch, HL Koo, KW Garey. Defining acute renal dysfunction as a criterion for *Clostridium difficile* infection severity in patients with community-onset vs. hospital-onset infection. *J Hosp Infect* 2013;83:294-9 PMID: 23433867
74. ZD Jiang, L Hoang, T Lasco, KW Garey, HL DuPont. Physician attitudes towards the use of fecal transplantation for recurrent *Clostridium difficile* infection in a large metropolitan city. *Clin Infect Dis* 2013;56(7):1059-60 PMID: 23223589
75. J Huang, ZD Jiang, KW Garey, T Lasco, and HL DuPont. Use of rifamycin drugs and the development of infection by rifamycin-resistant strains of *Clostridium difficile*. *Antimicrob Agents Chemother* 2013;57(6):2690-3 PMID: 23545528
76. CGM Jardin, HR Palmer, DN Shah, F Le, ND Beyda, ZD Jiang, KW Garey. Assessment of treatment patterns and patient outcomes pre- versus post-implementation of a severity-based *Clostridium difficile* infection treatment policy. *J Hosp Infect* 2013;85(1):28-32 PMID: 23834988
77. ND Beyda, MJ Alam, KW Garey. Comparison of the T2Dx instrument with T2Candida assay and automated blood culture in the detection of *Candida* species using simulated blood cultures. *Diagn Microbiol Infect Dis* 2013;77(4):324-6 PMID: 23834988
78. Wanat MA, Fleming ML, Fernandez JM, Garey KW. Education, training and academic experiences of newly hired first time faculty members. *Am J Pharm Educ* 2014;78(5):92. PMID: 24954932
79. Darkoh C, Turnwald BP, Koo HL, Garey KW, Jiang ZD, Aitken SL, Dupont HL. Colonic immunopathogenesis of *Clostridium difficile* infections. *Clin Vaccine Immunol* 2014;21(4):509-17 PMID: 24477852
80. HL Koo, JN Van, M Zhao, X Ye, PA Revell, ZD Jiang, CZ Grimes, DC Koo, T Lasco, CA Kozinetz, KW Garey, HL DuPont. Real-time Polymerase Chain Reaction Detection of Asymptomatic *Clostridium difficile* Colonization and Rising *Clostridium difficile*-Associated Disease Rates. *Infect Contr Hosp Epidemiol* 2014;35(6):667-43 PMID: 24799643
81. Alam MJ, Anu A, Walk ST, Garey KW Investigation of potentially pathogenic *Clostridium difficile* contamination in household environs. *Anaerobe* 2014;27:31-3 PMID: 24657158
82. SL Aitken, ND Beyda, DN Shah, HR Palmer, TM Lasco, H Koo, KW Garey. Clinical practice patterns in hospitalized patients at risk for invasive candidiasis: role of antifungal stewardship programs in an era of rapid diagnostics. *Ann Pharmacother* 2014;48(6):683-90 PMID: 24687545
83. Jacobs DM, Beyda ND, Asuphon O, Alam MJ, Garey KW. Host factors and clinical outcomes of *Candida* colonization in critically ill patients. *Mycopathologia* 2014 Aug 31. PMID: 25173925
84. Jacobs DM, Kuper K, Septimus E, Arafat R, Garey KW. Assessment of antimicrobial stewardship activities in a large metropolitan area. *J Pharm Pract* 2014 Oct 13. pii: 0897190014549842. PMID:25312262
85. SL Aitken, TB Joseph, DN Shah, TM Lasco, H Palmer, HL DuPont, Y Xie, and KW Garey. Healthcare resource utilization for recurrent *Clostridium difficile* infection in a large university hospital in Houston, Texas. *PLOS One* 2014 Jul 24;9(7):e102848. PMID: 25057871
86. ND Beyda, J John, A Kilic, MJ Alam, TM Lasco, KW Garey. *FKS* mutant *Candida glabrata*; risk factors and outcomes in patients with candidemia. *Clin Infect Dis* 2014;15;59(6):819-25. PMID: 24879785

87. Bernhardt MB, Moffett BS, Johnson M, Tam VH, Thompson P, Garey KW. Serial agreement among measurements and estimations of glomerular filtration in children with cancer. *Pediatr Blood Cancer*. 2015 Jan;62(1):80-4 PMID: 25263332
88. Aitken SL, Hemmige VS, Koo HL, Vuong NN, Lasco TM, Garey KW. Real-world performance of a microarray-based rapid diagnostic for Gram-positive bloodstream infections and potential utility for antimicrobial stewardship. *Diagn Microbiol Infect Dis* 2015;81(1):4-8 PMID:25445120
89. E Mylonakis, CJ Clancy, L Ostrosky-Zeichner, KW Garey, GJ Alangaden, JA Vazquez, JS Groeger, MA Judson, YM Vinagre, SO Heard, FN Zervou, IM Zacharioudakis, DP Kontoyiannis PG Pappas. T2 Magnetic Resonance Assay for the Rapid Diagnosis of Candidemia in Whole Blood: A Clinical Trial. *Clin Infect Dis* 2015;81(1):4-8. PMID: 25586686
90. Garey KW, Aitken SL, Dima-Ala A, Beyda ND, Kuper K, Xie Y, Koo HL. Echinocandin use in hospitalized patients: a multi-institutional study. *Amer J Med Sci* 2015 Jan 20. PMID:25607510
91. J Martinson, S Broadaway, E Lohman, C Johnson, MJ Alam, M Khaleduzzuman, KW Garey, J Schlackman, V Young, K Santhosh, K Rao, R Lyons, and S Walk. Evaluation of portability and cost of a fluorescent PCR ribotyping protocol for *Clostridium difficile* epidemiology. *J Clin Microbiol* 2015;53(4): 1192-7 PMID: 25631804
92. Philip A, Green M, Hoffman, T, Gautreaux S, Wallace D, Roux R, and Garey KW. Expansion of clinical pharmacy via increased utilization of outpatient pharmacists for telephone anticoagulation services. *Amer J Health Syst Pharm* 2015;72:536-7 PMID: 25788511
93. A Kilic, MJ Alam, NL Tisdell, DN Shah, M Yapar, TM Lasco, and KW Garey. Multiplex Real-Time PCR Method for Simultaneous Identification and Toxigenic Type Characterization of *Clostridium difficile* From Stool Samples. *Ann Lab Med* 2015;35(3): 306-13. PMID: 25932438
94. X Na, AJ Martin, S Sethi, L Kyne, KW Garey, SW Flores, M Hu, DN Shah, K Shields, DA Leffler, CP Kelly. A multi-center prospective derivation and validation of a clinical prediction tool for severe *Clostridium difficile* infection. *PLoS One*. 2015 Apr 23;10(4):e0123405.PMID: 25906284
95. H Yu, K Chen, J Wu, Z Yang, L Shi, LL Barlow, DM Aronoff , KW Garey, TC Savidge, EC von Rosenvinge, CP Kelly, and H Feng. Identification of toxemia in patients with *Clostridium difficile* infection. *PLoS One*. 2015 Apr 17;10(4):e0124235. .PMID: 25885671
96. Nesher L, Hadi CM, Salazar L, Wootton SH, Garey KW, Lasco T, Luce AM, Hasbun R. Epidemiology of meningitis with a negative CSF Gram stain: under-utilization of available diagnostic tests. *Epidemiol Infect*. 2015 May 20;1-9. PMID: 25989841
97. Philip A, Gessner-Wharton M, Birney P, Blee P, Desai A, Gorbach C, Karralli R, Lorimer D, Munch K, Nweke G, Parekh S, Puebla M, Cox R, Pitman E, Garey KW. A Pharmacy Practice Model Initiative taskforce to increase hospital self-assessment survey response rates and improve the understanding of pharmacy practice in Texas. *Am J Health Syst Pharm* 2015 Jun 15;72(12):1053-7. PMID: 26025997
98. Blee J, Roux RK, Gautreaux S, Sherer JT, Garey KW. Multidose Medication Dispensing on Discharge for Patients with Chronic Obstructive Pulmonary Disease: Effects on Adherence and Readmissions. *Amer J Health Syst Pharm* 2015;72:1204-8. PMID 26150571
99. ND Beyda, G Liao, BT Endres, RE Lewis, KW Garey. Innate inflammatory response and immunopharmacologic activity of micafungin, caspofungin, and voriconazole against wild-type and FKS mutant *Candida glabrata*. *Antimicrob Agents Chemother* 2015;59(9):5405-12 PMID: 26100700
100. VP Pham, AM Luce, SC Ruppelt, W Wei, SL Aitken, WL Musick, R Roux, and KW Garey. Age-stratified treatment response rates in hospitalized patients with *Clostridium difficile* infection treated with metronidazole. *Antimicrob Agents Chemother* 2015;59(10):6113-6 PMID: 26195522
101. Gorbach C, Blanton, L, Lukawski B, Varkey AC, Pitman P, Garey KW. Frequency of and risk factors for medication errors during the order-verification process in a large, tertiary care medical center. *Amer J Health Syst Pharm* 2015;72(17):1471-4 PMID: 26294240

102. SL Aitken, MJ Alam, M Khaleduzzaman, ST Walk, WL Musick, VP Pham, J Christensen, R Atmar, Y Xie, KW Garey. In the endemic setting, *Clostridium difficile* ribotype 027 is virulent but not hypervirulent. *Infect Contr Hosp Epidemiol* 2015;36(11):1318-23 PMID: 26288985
103. A Philip, A Desai, P Nguyen, P Birney, R Karralli, L Smith, D Lorimer, G Burgess, N Daniel, K Munch, J Lionetti, and KW Garey. Evaluating Pharmacy Leader Development Through The Seven Action Logics. *Amer J Health Syst Pharm* 2016;73:82-5 PMID 26721538
104. E Basseres, BT Endres, M Khaleduzzaman, F Miraftabi, MJ Alam, RJ Vickers, KW Garey. Impact on toxin production and cell morphology in *Clostridium difficile* by ridinilazole (SMT19969), a novel treatment for *C. difficile* infection. *J Antimicrob Chemother* 2016;71(5):1245-51. PMID: 26895772
105. AK Thabit, MJ Alam, M Khaleduzzaman, KW Garey, DP Nicolau. A pilot study to assess bacterial and toxin reduction in patients with *Clostridium difficile* infection given fidaxomicin or vancomycin. *Ann Clin Microbiol Antimicrob.* 2016 Apr 12;15(1):22.PMID 27071986.
106. BT Endres, E Bassères, A Memariani, L Chang, MJ Alam, RJ Vickers, IA Kakadiaris, KW Garey. A novel method for imaging the pharmacological effects of antibiotic treatment on *Clostridium difficile*. *Anaerobe* 2016;40:10-14. PMID: 27108094
107. BT Endres, E Bassères, M Khaleduzzan¹, MJ Alam, L Chesnel, and KW Garey. Evaluating the Effects of Surotomycin Treatment on *C. difficile* Toxin A and B Production, Immune Response, and Morphologic Changes. *Antimicrob Agents Chemother* 2016 May 23;60(6):3519-23. PMID: 27021314
108. KW Garey, SL Aitken, L Gschwind, S Goddu, Y Xie, C Duff, F Barbut, DN Shah, and HL DuPont. Development and Validation of a *Clostridium difficile* Health-related Quality of Life Questionnaire. *J Clin Gastro* 2016 Sep;50(8):631-7. PMID 26796081
109. DN Shah, SL Aitken, LF Barragan, S Bozorgui, S Goddu, ME Navarro, Y Xie, HL DuPont, and KW Garey. Economic burden of primary vs. recurrent *Clostridium difficile* infection in hospitalized patients; a prospective cohort study. *J Hosp Infect.* 2016 Jul;93(3):286-9. PMID: 27209056
110. DN Shah, F Chan, N Kachru, K Garcia, H Balcer, A Dyer, J Emanuel, M Jordan, K Lusardi, G Naymick, R Polisetty, L Sieman, A Tyler, M Johnson, KW Garey. A multi-center study of fidaxomicin use for *Clostridium difficile* infection SpringerPlus 2016;5(1):1224. PMID: 27536508
111. Shea KM, Hobbs AL, Jaso TC, Bissett JD, Cruz CM, Douglass ET, Garey KW. Effect of a Healthcare-system Respiratory Fluoroquinolone Restriction Program to Alter Utilization and Impact Rates of *C. difficile* Infection. *Antimicrob Agents Chemother.* 2017 Mar 27. PMID:28348151
112. MJ Alam, ST Walk, BT Endres, E Basseres, M Khaleduzzaman, J Amadio, WL Musick, JL Christensen, J Kuo, RL Atmar, and KW Garey. Community environmental contamination of toxigenic *Clostridium difficile*. *Open Forum Infect Dis* 2017 Feb 10;4(1):ofx018. doi: 10.1093/ofid/ofx018. eCollection 2017 Winter PMID: 28480289
113. SR Cox, MG Liebl, MN McComb, J Chau, AD Wilson, M Achi, KW Garey, D Wallace. Association between health literacy and 30-day healthcare use after hospital discharge in the heart failure population. *Res Soc Admin Pharm* 2016 Oct 14. pii: S1551-7411(16)30410-7 PMID: 28277275
114. Endres BT, Bassères E, Rashid T, Long C, Alam MJ, and Garey KW. A Protocol to Characterize the Morphological Changes of *Clostridium difficile* in Response to Antibiotic Treatment. *J Vis Exp* 2017 May 25;(123). doi: 10.3791/55383. PMID:28570548
115. H Yu, K Chen, Y Sun, M Carter, KW Garey, T Savidge, S Devaraj, M Tessier, E von Rosenvinge, C Kelly, M Pasetti, H Feng. Cytokines are markers of the *Clostridium difficile*-induced inflammatory response and predict disease severity. *Clin Vaccine Immunol.* 2017 Aug 4;24(8). pii: e00037-17. PMID: 28592627
116. JW Rogers, M Fleming, J Tipton, A Ward, KW Garey. Investigating inpatient medication administration using the theory of planned behavior. *Amer J Health Syst Pharm* 2017;74(24):2065-70 PMID 29222364

117. T Rashid, K Poblete, J Amadio, I Hasan, K Begum, MJ Alam, KW Garey. Evaluation of a shoe sole UVC device to reduce pathogen colonization on floors, surfaces, and patients. *J Hosp Infect*. 2018;98(1):96-101 PMID: 29066141
118. Bhakta SB, Colavecchia AC, Coffey W, Curlee DR, Garey KW. Implementation and evaluation of a sterile compounding robot in a satellite oncology pharmacy. *Am J Health Syst Pharm*. 2018 Jun 1;75(11 Supplement 2):S51-S57. PMID:29802179
119. CJ Clancy, PG Pappas, J Vazquez, M Judson, DP Kontoyiannis, GR Thompson, KW Garey, A Reboli, R Greenberg, S Apewokin, M Lyons, L Ostrosky-Zeichner, A Wu, E Tobin, MH Nguyen, AM Caliendo. Detecting Infections Rapidly and Easily for Candidemia Trial-2 (DIRECT2): A Prospective, Multicenter Study of the T2Candida Panel. *Clin Infect Dis*. 2018 2018 May 17;66(11):1678-1686. PMID:29438475
120. S Pattharachayakul, P Wongpoowarak, W Santimaleeworagun, P Tansakul, P Chayakul, and KW Garey. BLA_{oxa-23-like} presence and 29 KDA porin loss in carbapenem resistant *Acinetobacter baumannii* clinical isolates in Thailand. *Southeast Asian J Trop Med Public Health* 2018;49(3):401-8
121. KM Dotson, SL Aitken, A Sofjan, DN Shah, R Aparasu, and KW Garey. Outcomes associated with *Clostridium difficile* infection in patients with chronic liver disease. *Epidemiol Infect* 2018; 146(9):1101-1105 PMID 29739486
122. Sofjan AK, Musgrove RJ, Beyda ND, Russo HP, Lasco TM, Yau R, Restrepo A, Garey KW. Prevalence and predictors of spontaneous bacterial peritonitis due to ceftriaxone-resistant organisms at a large tertiary center in the United States. *J Glob Antimicrob Resist*. 2018 May 26;15:41-47. PMID: 29842975
123. JN Addo Smith, R Yau, HP Russo, K Putney, A Restrepo, KW Garey, AK Sofjan. Bacteremia in patients with liver cirrhosis: prevalence and predictors of multidrug resistant organisms. *J Clin Gastroenterol* 2018 Aug;52(7):648-654. PMID: 29176351
124. AK Sofjan, A Mitchell, DN Shah, T Nguyen, M Sim, A Trojcek, ND Beyda, KW Garey. Rezafungin (CD101), a next generation echinocandin. A systematic literature review and assessment of possible place in therapy. *J Glob Antimicrob Resist* 2018 Sep;14:58-64. PMID:29486356
125. AK Sofjan, B Casey, BA Xu, J Amadio, A Restrepo, MJ Alam, KW Garey. Accelerate PhenoTest™ BC Kit vs. Conventional Methods for Gram-positive Bloodstream Infections: Diagnostic Performance and implications for Antimicrobial Stewardship. *Ann Pharmacother* 2018 Aug;52(8):754-762. PMID: 29557208
126. Davis ML, Sparrow HG, Ikwuagwu JO, Musick WK, Garey KW, Perez KK. A multi-center derivation and validation of a simple predictive index for healthcare-associated *Clostridium difficile* infection. *Clin Microbiol Infect* 2018 Nov;24(11):1190-1194. PMID:29454848
127. BT Endres, KM Dotson, K Poblete, J McPherson, C Lancaster, E Bassères, A Memariani, S Arnold, S Tupy, C Carlsen, B Morehead, S Anyatonwu, C Cook, K Begum, MJ Alam, KW Garey. Environmental transmission of *Clostridioides difficile* ribotype 027 at a long-term care facility; an outbreak investigation guided by whole genome sequencing. *Infect Control Hosp Epidemiol* 2018 Nov;39(11):1322-1329 PMID:30253813
128. McDonald LC, Johnson S, Bakken JS, Garey KW, Kelly C, Gerding DN. Reply to Fabre et. al. *Clin Infect Dis*. 2018 May 31. doi: 10.1093/cid/ciy475. PMID: 29860268
129. ND Beyda, J Amadio, JR Rodriguez, K Malinowski, KW Garey, A Wanger, L Ostrosky-Zeichner. In vitro evaluation of BacT/Alert FA blood Culture bottles and T2Candida assay for the detection of *Candida* in the presence of antifungals. *J Clin Microbiol* 2018 Jun 13. pii: JCM.00471-18. doi: 10.1128/JCM.00471-18. PMID:29898999
130. KR Reveles, KM Dotson, A Gonzales-Luna, D Surati, BT Endres, MJ Alam, KW Garey. *Clostridioides* (formerly *Clostridium*) *difficile* infection during hospitalization increases the likelihood of non-home patient discharge. *Clin Infect Dis*. 2019 May 17;68(11):1887-1893. PMID:30204878

131. E Skoglund, C Dempsey, H Chen, KW Garey Estimated clinical and economic impact through use of a novel blood collection device to reduce blood culture contamination in the emergency department: A cost-benefit analysis. *J Clin Microbiol.* 2019 Jan 2;57(1). pii: e01015-18. doi: 10.1128/JCM.01015-18. PMID:30355758
132. MA Islam, ND Kabir, M Moniruzzaman, K Begum, D Ahmed, ASG Faruque, KW Garey, MJ Alam. *Clostridioides difficile* ribotypes isolated from domestic environment and from patients in Bangladesh. *Anaerobe* 2019;56:88-90.PMID:30794875
133. KL Yee, HJ Kleijn, T Kerbusch, RP Matthews, MB Dorr, KW Garey, RE Wrishko. Population pharmacokinetics and pharmacodynamics of bezlotoxumab in adults with primary and recurrent *Clostridium difficile* infection. *Antimicrob Agents Chemother* 2018 Nov 19. pii: AAC.01971-18. doi: 10.1128/AAC.01971-18. PMID:30455246
134. SB Bhakta, AC Colavecchia, L Haines, D Varkey, KW Garey. A Systematic Approach to Optimize Health-System Electronic Health Record Medication Alerts. *Amer J Health-syst Pharm* 2019 Apr 8;76(8):530-536. doi: 10.1093/ajhp/zxz012. PMID:31361861
135. BT Endres, K Begum, H Sun, ST Walk, A Memariani, C Lancaster, AJ Gonzales-Luna, KM Dotson, E Bassères, C Offiong, S Tupy, K Kuper, E Septimus, R Arafat, MJ Alam, Z Zhao, JG Hurdle, TC Savidge, KW Garey. Early emergence of epidemic *Clostridioides difficile* ribotype 027 lineages in the US: implications for fluoroquinolone use. *Open Forum Infect Dis* 2019;6(2)ofz013 PMID: 30793006
136. MA Engevik, B Luk, AL Chang-Graham, A Hall, B Herrmann, W Ruan, BT Endres, Z Shi, KW Garey, J Hyser, J Versalovic. *Bifidobacterium dentium* fortifies the intestinal mucus layer via autophagy and calcium signaling pathways. *MBio* 2019 Jun 18;10(3). pii: e01087-19. doi: 10.1128/mBio.01087-19. PMID: 31213556
137. MJ Alam, J McPherson, J Miranda, A Thrall, V Ngo, R Kessinger, K Begum, M Marin, KW Garey. Molecular epidemiology of *Clostridioides difficile* in domestic dogs and zoo animals. *Anaerobe* 2019 Jun 14. pii: S1075-9964(19)30102-7. doi: 10.1016/j.anaerobe.2019.06.005. PMID: 31207298
138. K Rainha, RF Ferreira, CN Trindade, LG Carneiro, B Penna, BT Endres, K Begum, MJ Alam, KW Garey, R Maria, C Domingues, E Ferreira. Characterization of *Clostridioides difficile* ribotypes in domestic dogs in Rio de Janeiro, Brazil. *Anaerobe* 2019 Jun 17. pii: S1075-9964(19)30104-0. doi: 10.1016/j.anaerobe.2019.06.007. PMID:31220606
139. Q Lin, NR Pollock, A Banz, A Lantz, H Xu, L Gu, DN Gerding, KW Garey, AJ Gonzales-Luna, M Zhao, L Song, DC Duffy, CP Kelly, X Chen. Toxin A-predominant Pathogenic *C. difficile*: A Novel Clinical Phenotype. *Clin Infect Dis* 2019 Aug 11. pii: ciz727. doi: 10.1093/cid/ciz727. PMID: 31400280
140. AK Sofjan, MA Islam, K Halder, ND Kabir, AA Saleh, J Miranda, C Lancaster, K Begum, MJ Alam, KW Garey. Molecular epidemiology of *Clostridioides difficile* isolates from hospitalized patients and the hospital environment in Dhaka, Bangladesh. *Anaerobe* 2019 Jul 26:102081. doi: 10.1016/j.anaerobe.2019.102081. PMID: 31356958
141. T Rashid, F Haghighi, I Hasan, E Bassères, MJ Alam, SV Sharma, D Lai, HL DuPont, KW Garey. Activity of Hospital Disinfectants against Vegetative Cells and Spores of *Clostridioides difficile* Embedded in Biofilms. *Antimicrob Agents Chemother* 2019 Oct 14. pii: AAC.01031-19. doi: 10.1128/AAC.01031-19. PMID 31611365
142. Shelburne S, Dib R, Endres BT, Reitzel R, Li X, Kalia A, Sahasrabhojane P, Chaftari AM, Hachem R, Vargas-Cruz N, Jiang Y, Garey KW, Fowler V, Holland T, Gu J, Miller M, Sakurai A, Arias C, Aitken S, Greenberg D, Kim, J, Raad I. Whole genome sequencing of *Staphylococcus epidermidis* bloodstream isolates from a prospective clinical trial reveals that complicated bacteremia is caused by a limited number of closely related sequence types. *Clin Microbiol Infect* 2019 Oct 19. pii: S1198-743X(19)30535-X. doi: 10.1016/j.cmi.2019.10.008. PMID 31639470

143. WJ Shen, A Deshpande, KE Hevener, BT Endres, KW Garey, K Palmer, JG Hurdle. Constitutive Expression of the Cryptic *vanG_{cd}* Operon Promotes Vancomycin Resistance in *Clostridioides difficile* Clinical Isolates, *J Antimicrob Chemother* [published online ahead of print, 2019 Dec 24];dkz513. doi:10.1093/jac/dkz513 PMID: 31873741
144. VH Tam, D Cohen, K Ledesma, B Guillory, K Chan, KW Garey. Local Tissue Response to Subcutaneous Administration of Ceftriaxone in an Animal Model. [published online ahead of print, 2019 Dec 23]. *Antimicrob Agents Chemother* 2019;AAC.02090-19. doi:10.1128/AAC.02090-19. PMID 31871078
145. Smith DV, Gautreaux S, Gulbis AM, Bruno JJ, Garey K, Roux RK, Varkey D. Program development of a preceptor bootcamp for operational pharmacy preceptors. *Am J Health Syst Pharm*, Volume 77, Issue Supplement_1, 1 March 2020, Pages S2–S7. PMID:31950136
146. TJ Carlson, BT Endres, JL Pham, AJ Gonzales-Luna, FS Alnezary, K Nebo, J Miranda, C Lancaster, E Bassères, K Begum, MJ Alam, KR Reveles, KW Garey. Eosinopenia and binary toxin increases mortality in hospitalized patients with *Clostridioides difficile* infection. *Open Forum Infect Dis* 2020 Jan 4;7(1):ofz552. doi: 10.1093/ofid/ofz552. PMID: 31993458;
147. AJ Gonzales-Luna, TJ Carlson, KM Dotson, K Poblete, G Costa, J Miranda, C Lancaster, S Walk, S Tupy, K Begum, MJ Alam, KW Garey. PCR ribotypes of *Clostridioides difficile* Across Texas from 2011-2018 including Emergence of Ribotype 255. *Emerg Microbes Infect* 2020; 9(1):341–347. PMID 32037964
148. Alosaimy S, Jorgensen SCJ, Lagnf AM, Melvin S, Mynatt RP, Carlson TJ, Garey KW, Allen D, Venugopalan V, Veve M, Athans V, Saw S, Yost CN, Davis SL, Rybak MJ. Real-world Multicenter Analysis of Clinical Outcomes and Safety of Meropenem-Vaborbactam in Patients Treated for Serious Gram-Negative Bacterial Infections. *Open Forum Infect Dis* 2020;7(3):ofaa051. doi: 10.1093/ofid/ofaa051. PMID:32161775
149. M Engevik, H Danhof, A Chang-Graham, J Spinler, K Engevik, B Hermann, BT Endres, KW Garey, J Hyser, R Britton, J Versalovic. Human intestinal enteroids as a model of *Clostridioides difficile*-induced enteritis. *Am J Physiol Gastrointest Liver Physiol* 2020. doi: 10.1152/ajpgi.00045.2020.PMID: 32223302
150. RL Hengel, TE Ritter, R Nathan, LJ Van Anglen, CP Schroeder, RJ Dillon, SW Marcella, and KW Garey. Real-World Experience of Bezlotoxumab for Prevention of *Clostridioides Difficile* Infection. *Open Forum Infect Dis*. 2020 Mar 19;7(4):ofaa097. doi: 10.1093/ofid/ofaa097. PMID: 32363211
151. ER Dubberke, DN Gerding, CP Kelly, KW Garey, G Rahav, A Mosley, R Tipping, MB Dorr. Efficacy of Bezlotoxumab in Participants Receiving Metronidazole, Vancomycin, or Fidaxomicin for Treatment of *Clostridioides* (*Clostridium*) *difficile* Infection. *Open Forum Infect Dis* 2020 Jun 2;7(6):ofaa157. doi: 10.1093/ofid/ofaa157. PMID: 32523972
152. K Begum, E Bassères, J Miranda, C Lancaster, AJ Gonzales-Luna, TJ Carlson, T Rashid, DW Eyre, MH Wilcox, MJ Alam, and KW Garey. In vitro Activity of Omadacycline, a New Tetracycline Analog, and Comparators Against *Clostridioides difficile*. *Antimicrob Agents Chemother* Jun 8;AAC.00522-20. doi: 10.1128/AAC.00522-20. PMID: 32513796
153. E Skoglund, J Fernandez, JT Sherer, KW Garey, EA Coyle, ML Fleming, AK Sofjan. Factors that influence students' intention to attend lectures in a PharmD program using the theory of planned behavior. *Amer J Pharm Educ* 2020 May;84(5):7550. doi: 10.5688/ajpe7550.PMID: 32577029
154. Basseres E, Begum, K, Lancaster C, Gonzales-Luna AJ, Carlson TJ, Miranda J, Rashid T, Alam MJ, Eyre DW, Wilcox MH and Garey KW. In vitro activity of eravacycline against common ribotypes of *Clostridioides difficile*. *J Antimicrob Chemother* 2020 Jul 28;dkaa289. doi: 10.1093/jac/dkaa289.PMID: 32719870
155. Engevik MA, Luck B, Visuthranukul C, Ihekweazu FD, Engevik AC, Shi Z, Danhof HA, Chang-Graham A, Hall A, Endres BT, Haidacher SJ, Horvath TD, Haag AM, Devaraj S, Garey KW, Britton RA, Hyser JM, Shroyer NF, Versalovic J. Human-derived *Bifidobacterium dentium* modulates the

- mammalian serotonergic system and gut-brain axis. *Cell Mol Gastroenterol Hepatol*. 2020 Aug 11:S2352-345X(20)30126-0. doi: 10.1016/j.jcmgh.2020.08.002. PMID: 32795610
156. Yepez Guevara EA, Aitken SL, Olvera AV, Carlin L, Fernandes KE, Bhatti MM, Garey KW, Adachi J, Okhuysen PC. *Clostridioides difficile* infection in cancer and immunocompromised patients: Relevance of a two-step diagnostic algorithm and infecting ribotypes on clinical outcomes. *Clin Infect Dis*. 2020 Aug 17:ciaa1184. doi: 10.1093/cid/ciaa1184. PMID: 32803229
 157. Crutchley RD, Jacobs DM, Gathe J, Mayberry C, Bulayeva N, Rosenblatt KP, Garey KW. Assessing changes in vitamin D over 48 weeks in treatment-naïve HIV individuals starting lopinavir/ritonavir monotherapy. *Curr HIV Res* 2020 Aug 27 doi: 10.2174/1570162X18666200827115615. PMID 32860360
 158. Garey KW, Begum K, Lancaster C, Gonzales-Luna AJ; Bui D, Mercier J, Corinne, SY, Ducharme MP, Hu M, Vince B, Silverman MH, Alam MJ, Kankam M. Randomized, Double blind, Placebo controlled, Single and Multiple Ascending Dose Phase 1 Study to Determine the Safety, Pharmacokinetics, Food, and Fecal Microbiome Effects of Ibezapolstat Administered Orally to Healthy Subjects. *J Antimicrob Chemother* 2020 Sep 6:dkaa364. doi: 10.1093/jac/dkaa364. PMID: 32892222
 159. AK Thabit, KM Shea, OE Guzman, and KW Garey. Antibiotic Utilization within 18 Community Hospitals in the United States: a 5-year Analysis. *Pharmacoepidemiol Drug Safety* 2020 Oct 23;doi: 10.1002/pds.5156 PMID 33094502
 160. R Sprague, K Warny, N Pollock, K Daugherty, Q Lin, H Xu, C Cuddemi, C Barrett, X Chen, A Banz, A Lantz, KW Garey, AJ Gonzales-Luna, CD Alonso, JA Villafuerte Galvez, CP Kelly. Absence of Toxemia in *Clostridioides difficile* infection: Results from Ultrasensitive Toxin Assay of Serum. *Dig Dis Sci*. Nov 8. doi: 10.1007/s10620-020-06683-8. PMID: 33164145
 161. TJ Carlson, AJ Gonzales-Luna, K Nebo, HY Chan, NLT Tran, S Antony, C Lancaster, MJ Alam, K Begum, and KW Garey. Assessment of Kidney Injury as a Severity Criteria for *Clostridioides difficile* Infection. *Open Forum Infect Dis* 2020 Oct 7;7(11):ofaa476. doi: 10.1093/ofid/ofaa476. PMID: 33209956
 162. M Engevik, H Danhof, J Auchtung, BT Endres, W Ruan, E Bassères, Q Wu, M Nicholson, RA Luna, KW Garey, SE Crawford, MK Estes, R Lux, MB Yacyshyn, B Yacyshyn, T Savidge, R Britton, J Versalovic. *Fusobacterium nucleatum* adheres to *Clostridioides difficile* via the RadD adhesin to enhance biofilm formation in intestinal mucus. *Gastroenterology* 2020 Nov 20:S0016-5085(20)35437-8. doi: 10.1053/j.gastro.2020.11.034. PMID: 33227279
 163. Asias-Dinh BD, Garey KW. Factors associated with abnormal glucose readings in a pharmacy-led community health fair using the ADA risk assessment tool. *J Am Pharm Assoc* (2003). 2020 Nov 27:S1544-3191(20)30551-3. PMID: 33257174
 164. TM Kiles, AV Zhao, MA Wanat, KW Garey, CL Hatfield. Knowledge and self-perception comparisons between students with and without prior technician experience in community pharmacy lab courses. *Curr Pharm Teach Learn* 2021;13:279-87 PMID: 33641739
 165. TM Kiles, KW Garey, MA Wanat, P Pitman. A survey to assess experiences and social support of underrepresented minority doctor of pharmacy students. *Curr Pharm Teach Learn* 2021;13:245-54 PMID: 33641734
 166. E Bassères, BT Endres, N Montes-Bravo, N Pérez-Soto, T Rashid, C Lancaster, K Begum, MJ Alam, D Paredes-Sabja, and KW Garey. Visualization of fidaxomicin association with the exosporium layer of *Clostridioides difficile* spores. *Anaerobe* 2021 Feb 25;102352. doi: 10.1016/j.anaerobe.2021.102352. PMID: 33640461
 167. Engevik MA, Danhof HA, Hall A, Engevik KA, Horvath TD, Haidacher SJ, Hoch KM, Endres BT, Bajaj M, Garey KW, Britton RA, Spinler JK, Haag AM, Versalovic J. The metabolic profile of *Bifidobacterium dentium* reflects its status as a human gut commensal. *BMC Microbiol* 2021; 21(1):154. doi: 10.1186/s12866-021-02166-6. PMID:34030655

168. AJ Gonzales-Luna, JK Spinler, N Oezguen, Md AW Khan, HA Danhof, BT Endres, MJ Alam, K Begum, C Lancaster, GPD Costa, TC Savidge, JG Hurdle, R Britton, and KW Garey. Systems biology evaluation of refractory *Clostridioides difficile* infection including multiple failures of fecal microbiota transplantation. *Anaerobe* 2021 May 24:102387. doi: 10.1016/j.anaerobe.2021.102387 PMID 34044101
169. S Ke, NR Pollock, XW Wang, X Chen, K Daugherty, KW Garey, AJ Gonzales-Luna, CP Kelly, YY Liu. Integrating Gut Microbiota and Immune Markers for Highly Accurate Diagnosis of *Clostridioides difficile* Infection. *Gut Microbes* 2021 Jan-Dec;13(1):1-18. doi: 10.1080/19490976.2021.1935186. PMID: 34132169
170. X Wu, WJ Shen, A Deshpande, A Olaitan, KL Palmer, KW Garey, JG Hurdle. The Integrity of Heme Is Critical For Reproducibly Detecting Metronidazole-Resistant *Clostridioides difficile* By Agar Dilution Susceptibility Tests. *J Clin Microbiol* 2021 Jun 16:JCM0058521. doi: 10.1128/JCM.00585-21. PMID: 34132582
171. A Miles-Jay, VB Young, EG Pamer, TC Savidge, M Kamboj, KW Garey, ES Snitkin A multisite genomic epidemiology study of *Clostridioides difficile* infections in the U.S. supports differential roles of healthcare versus community spread for two common strains. *Microb Genom* 2021 Jun;7(6). doi: 10.1099/mgen.0.000590. PMID: 34180789
172. AJ Gonzales-Luna, AO Olaitan, WJ Shen, A Deshpande, TJ Carlson, KM Dotson, C Lancaster, K Begum, MJ Alam, JG Hurdle, KW Garey. Reduced susceptibility to metronidazole is associated with initial clinical failure in *Clostridioides difficile* infection. *Open Forum Infect Dis*, 2021 July 8; ofab365. Doi: 10.1093/ofid/ofab365 PMID: 34381844
173. Alosaimy S, Lagnf AM, Morrisette T, Scipione MR, Zhao JJ, Jorgensen SCJ, Mynatt R, Carlson TJ, Jo J, Garey KW, Allen D, DeRonde K, Vega AD, Abbo LM, Venugopalan V, Athans V, Saw S, Claeys KC, Miller M, Molina KC, Veve M, Kufel WD, Amaya L, Yost C, Ortwine J, Davis SL, Rybak MJ. Real-world, Multicenter Experience With Meropenem-Vaborbactam for Gram-Negative Bacterial Infections Including Carbapenem-Resistant Enterobacterales and *Pseudomonas aeruginosa*." *Open Forum Infect Dis* 2021 8(8): ofab371 doi: 10.1093/ofid/ofab371 PMID: 34430671
174. MS Almutairi, AJ Gonzales-Luna, FS Alnezary, S Fallatah, MJ Alam, K Begum and KW Garey Comparative clinical outcomes evaluation of hospitalized patients infected with *Clostridioides difficile* ribotype 106 vs. other toxigenic strains. *Anaerobe* 2021 Aug 27;102440. doi: 10.1016/j.anaerobe.2021.102440. PMID: 34461273
175. CD Alonso, CP Kelly, KW Garey, AJ Gonzales-Luna, D Williams, K Daugherty, C Cuddemi, J Villafuerte-Gálvez, NC White, X Chen, H Xu, R Sprague, C Barrett, M Miller, A Foussadier, A Lantz, A Banz, NR Pollock. Ultrasensitive and quantitative toxin measurement correlates with baseline severity, severe outcomes, and recurrence among hospitalized patients with *Clostridioides difficile* infection. *Clin Infect Dis* 2021 Sep 19:ciab826. doi: 10.1093/cid/ciab826. PMID: 34537841
176. CD Alonso, K Papamichael, R Sprague, C Barrett, AJ Gonzales-Luna, K Daugherty, KW Garey, J Villafuerte-Gálvez, H Xu, X Chen, N Pollock, CP Kelly. Humoral Immune Response to *Clostridioides difficile* Toxins A and B in Hospitalized Immunocompromised Patients with *C. difficile* infection. *Open Forum Infect Dis* 2021 Jun 1;8(7):ofab286. doi: 10.1093/ofid/ofab286 PMID: 34258317
177. Han Z, Lapin B, Garey KW, Donskey CJ, Deshpande A. Impact of *Clostridioides difficile* infection on patient-reported quality of life. *Infect Control Hosp Epidemiol*. 2021 Oct 7:1-6. doi: 10.1017/ice.2021.413. PMID: 34615561
178. TJ Carlson, AJ Gonzales-Luna, MF Wilcox, SG Theriault, FS Alnezary, P Patel, BK Ahn, EJ Zasowski, KW Garey. Corticosteroids Do Not Increase the Likelihood of Primary *Clostridioides difficile* Infection in the Setting of Broad-spectrum Antibiotic Use. *Open Forum Infect Dis* 2021 Aug 11;8(10):ofab419. doi: 10.1093/ofid/ofab419. PMID: 34646906
179. Rainha K, Lins Dé, Ferreira RF, Costa CL, Penna B, Endres BT, Garey KW, Domingues RMCP, Ferreira EO, Colitis caused by *Clostridioides difficile* infection in a domestic dog. *Anaerobe* 2022, doi: <https://doi.org/10.1016/j.anaerobe.2021.102511>. PMID:34990816

180. N Deyhim, SB Bhakta, AC Varkey, DL Metzen, D Varkey, RJ Martinez, KW Garey. Systemization of a pharmacy technician career ladder in a multi-hospital system. *Exploratory Research in Clinical and Social Pharmacy* 2021;2:100036. doi: 10.1016/j.rcsop.2021.100036. PMID:35481131
181. KW Garey, J McPherson, AQ Dinh, C Hu, J Jo, W Wang, CK Lancaster, AJ Gonzales-Luna, C Loveall, K Begum, MJ Alam, MH Silverman, and B Hanson. Efficacy, Safety, Pharmacokinetics, and Microbiome Changes of Ibezapolstat in Adults with *Clostridioides difficile* Infection: A Phase 2a Multicenter Clinical Trial. *Clin Infect Dis*. 2022 Feb 4:ciac096. doi: 10.1093/cid/ciac096 PMID: 35134880
182. J Jo, AJ Gonzales-Luna, CK Lancaster, JK McPherson, K Begum, MJ Alam, KW Garey. Multi-Country Surveillance of *Clostridioides difficile* Demonstrates High Prevalence of Spores in Non-Healthcare Environmental Settings. *Anaerobe* 2022 doi:10.1016/j.anaerobie.2022.102543 PMID 35227896
183. C Hu, ND Beyda, KW Garey. A Vancomycin HPLC Assay for Use in Gut Microbiome Research. *Microbiol Spectr* 2022 May 10:e0168821. doi: 10.1128/spectrum.01688-21. PMID: 35536037
184. RL Hengel, CP Schroeder, J Jo, TE Ritter, RV Nathan, AJ Gonzales-Luna, EN Obi, RJ Dillon, LJ Van Anglen and KW Garey. Recurrent *Clostridioides difficile* Infection Worsens Anxiety-Related Patient-Reported Quality of Life. *J Patient Rep Outcomes* 2022;6:49. doi.org/10.1186/s41687-022-00456-9 PMID 35567724
185. J McPherson, C Hu, K Begum, W Wang, C Lancaster, AJ Gonzales-Luna, C Loveall, MH Silverman, MJ Alam, and KW Garey. Functional and Metagenomic Evaluation of Ibezapolstat for Early Evaluation of Anti-recurrence Effects in *Clostridioides difficile* Infection. *Antimicrob Agents Chemother* 2022 Jul 6:e0224421. doi: 10.1128/aac.02244-21. PMID: 35862742
186. Lapin B, Garey KW, Wu H, Sissi V, Huang SP, Reese PR, Wang E, Deshpande A. Validation of a health-related quality of life questionnaire in patients with recurrent *Clostridioides difficile* infection in ECOSPOR III, a Phase 3 randomized trial. *Clin Infect Dis*. 2022 Jul 5:ciac554. doi: 10.1093/cid/ciac554. PMID: 35789381
187. Sandora TJ, Williams DN, Daugherty K, Geer C, Cuddemi C, Kociolek LK, Chen X, Xu H, Savage TJ, Banz A, Garey KW, Gonzales-Luna AJ, Kelly CP, Pollock NR. Stool Toxin Concentration Does Not Distinguish *Clostridioides difficile* Infection from Colonization in Children Less Than 3 Years of Age. *J Pediatric Infect Dis Soc*. 2022 Jul 8:piac059. doi: 10.1093/jpids/piac059.PMID: 35801632
188. J Jo, TT Tran, ND Beyda, D Simmons, J Hendrickson, MS Almutairi, FS Alnezary, AJ Gonzales-Luna¹, EJ Septimus, and KW Garey. Development of the Invasive Candidiasis Discharge [I Can Discharge] Model, a mixed methods analysis. *Eur J Clin Microbiol Infect Dis* 2022 Oct;41(10):1207-1213. doi: 10.1007/s10096-022-04473-w. PMID: 36002777
189. JA Villafuerte Gálvez, NR Pollock, CD Alonso, X Chen, H Xu, L Wang, N White, A Banz, K Daugherty, AJ Gonzalez-Luna, C Barrett, R Sprague, KW Garey, CP Kelly. Stool interleukin-1 β differentiates *Clostridioides difficile* infection from asymptomatic carriage and non-CDI diarrhea. *Clin Infect Dis* 2022 Jul 30:ciac624. doi: 10.1093/cid/ciac624. PMID: 35906836
190. Schroeder CP, Hengel RL, Nathan RV, Ritter TE, Obi EN, Lancaster C, Van Anglen LJ, Garey KW. Appropriate cleaning reduces potential risk of spore transmission from patients with *Clostridioides difficile* infection treated in outpatient infusion centers. *Anaerobe*. 2022 Aug 5:102617. doi: 10.1016/j.anaerobe.2022.102617. PMID: 35940371
191. Francisco DMA, Zhang L, Jiang Y, Olvera A, Adachi J, Guevara EY, Aitken SL, Garey KW, Peterson CB, Do KA, Dillon R, Obi EN, Jenq R, Okhuysen PC. Risk Factors Associated with Severe *Clostridioides difficile* Infection in Patients with Cancer. *Infect Dis Ther*. 2022 Nov 28. doi: 10.1007/s40121-022-00722-9. PMID: 36443547
192. C Hu, W Wang, KW Garey. Heterogeneity and lyophilization comparison of stool processing for gastrointestinal bile acid measurement by LC-MS/MS. *J Chromatogr B Analyt Technol Biomed Life Sci* 2022 Dec 9;1214:123569. doi: 10.1016/j.jchromb.2022.123569. PMID: 36527807

193. BT Endres, E Basseres, DM Citron, KL Tyrrell, K Begum, C Lancaster, YA Warren, MJ Alam, KW Garey, and EJC Goldstein. Fusobacteria behaving badly: masquerading strains of Strictly Anaerobic *Escherichia coli* misidentified due to the Deletion of the *hemB* gene. *Anaerobe* 2022 doi: 10.1016/j.anaerobe.2022.102682.PMID: 36580991
194. Sandora TJ, Kocielek LK, Williams DN, Daugherty K, Geer C, Cuddemi C, Chen X, Xu H, Savage TJ, Banz A, Garey KW, Gonzales-Luna AJ, Kelly CP, Pollock NR. Baseline stool toxin concentration is associated with risk of recurrence in children with *Clostridioides difficile* infection. *Infect Control Hosp Epidemiol* 2023 Jan 10:1-7. doi: 10.1017/ice.2022.310. PMID: 36624698
195. Tran TT, Cabrera NL, Gonzales-Luna AJ, Carlson TJ, Alnezary F, Miller WR, Sakurai A, Dinh AQ, Rydell K, Rios R, Diaz L, Hanson BM, Munita JM, Pedroza C, Shelburne SA, Aitken SL, Garey KW, Dillon R, Puzniak L, Arias CA. Clinical characteristics, microbiology and outcomes of a cohort of patients treated with ceftolozane/tazobactam in acute care inpatient facilities, Houston, Texas, USA. *JAC Antimicrob Resist.* 2023;5(1):dlac131. doi: 10.1093/jacamr/dlac131. PMID: 3660155
196. KW Garey, J Jo, AJ Gonzales-Luna, B Lapin, A Deshpande, E Wang, B Hasson, SV Pham, SP Huang, PR Reese, H Wu, E Hohmann, P Feuerstadt, C Oneto, CS Berenson, C Lee, B McGovern, L von Moltke. Impact of Investigational Oral Microbiome Therapeutic SER-109 on Quality-of-Life in Recurrent *Clostridioides difficile* Infection: a Randomized Controlled Trial. *JAMA Network Open* 2023;6(1):e2253570. PMID:36716031
197. Gonzales-Luna AJ, Dureja C, Eubank TA, Garey KW, Hurdle JG. Surveillance of *Clostridioides difficile* antimicrobial resistance in the United States. *Clin Infect Dis.* 2023 Mar 8:ciad135. doi: 10.1093/cid/ciad135.PMID: 36883582
198. Banegas M, Villafuerte-Gálvez J, Paredes R, Sprague R, Barrett C, Gonzales-Luna AJ, Daugherty K, Garey KW, Xu H, Lin Q, Wang L, Chen X, Pollock NR, Kelly CP, Alonso CD. Preservation of the Innate Immune Response to *Clostridioides difficile* Infection in Hospitalized Immunocompromised Patients. *Open Forum Infect Dis.* 2023 Feb 18;10(3):ofad090. doi: 10.1093/ofid/ofad090. PMID:36949876
199. Garey KW, Feuerstadt P, Dubberke ER, Guo A, Tillotson GS. Effect of fecal microbial transplantation on *Clostridioides difficile* infection: dysbiosis, metabolites and health related quality of life. *Open Forum Infect Dis.* 2023 Mar 24;10(3):ofad113. doi: 10.1093/ofid/ofad113. PMID: 36968968
200. A Zaki, AJ Gonzales-Luna, ND Beyda, T Lasco, and KW Garey. Micafungin Pharmacodynamics Predict Clinical Outcomes in Hospitalized Patients with Candidemia caused by certain *Candida* species. *Pharmacother* 2023 doi: 10.1002/phar.2804 PMID: 37067155
201. Gonzales-Luna AJ, Skinner AM, Alonso CD, Bouza E, Cornely OA, de Meij TGJ, Drew RJ, Garey KW, Gerding DN, Johnson S, Kahn SA, Kato H, Kelly CP, Kelly CR, Kocielek LK, Kuijper EJ, Louie T, Riley TV, Sandora TJ, Vehreschild MJGT, Wilcox MH, Dubberke ER; EXPAND Cdiff group. Redefining *Clostridioides difficile* infection antibiotic response and clinical outcomes. *Lancet Infect Dis* 2023 S1473-3099(23)00047-6. doi: 10.1016/S1473-3099(23)00047-6. PMID: 37062301
202. CS Mason, T Avis, C Hu, N Nagalingam, M Mudaliar, C Coward, K Begum, K Gajewski, MJ Alam, E Bassères, S Moss, S Reich, E Duperchy, KR Fox, KW Garey, and DJ Powell. The novel DNA binding mechanism of ridinilazole, a precision *Clostridioides difficile* antibiotic. *Antimicrob Agents Chemother* 2023:e0156322. doi: 10.1128/aac.01563-22. PMID: 37093023
203. Zasowski EJ, Ali M, Anugo A, Ibragimova N, Dotson KM, Endres BT, Begum K, Alam MJ, Garey KW. Comparison of Risk Stratification Approaches to Identify Patients with *Clostridioides difficile* Infection at Risk for Multidrug-Resistant Organism Gut Microbiota Colonization. *Infect Dis Ther.* 2023 Jul 12. doi: 10.1007/s40121-023-00843-9.PMID: 37436677
204. Olaitan AO, Dureja C, Youngblom MA, Topf MA, Shen WJ, Gonzales-Luna AJ, Deshpande A, Hevener KE, Freeman J, Wilcox MH, Palmer KL, Garey KW, Pepperell CS, Hurdle JG. Decoding a cryptic mechanism of metronidazole resistance among globally disseminated fluoroquinolone-resistant *Clostridioides difficile*. *Nat Commun.* 2023 Jul 12;14(1):4130. doi: 10.1038/s41467-023-39429-x.PMID: 37438331

205. Q Wu, P Boonma, S Badu, N Yalcinkaya, SY So, KW Garey, K Williams, LE Arnold, R Shulman, R Kellermayer, T Savidge. Donor-recipient specificity and age-dependency in fecal microbiota therapy and probiotic resolution of gastrointestinal symptoms. NPJ Biofilms Microbiomes 2023;9(1):54. PMID. 37537181
206. KW Garey, ER Dubberke, A Guo, A Harvey, M Yang, V García-Horton, M Fillbrunn, H Wang, GS Tillotson, LL Bancke, P Feuerstadt. Effect of Fecal Microbiota, live-jslm (RBL) on Health-Related Quality of Life in Patients with Recurrent *Clostridioides difficile* Infection: Results from the PUNCH CD3 Clinical Trial. Open Forum Infect Dis. 2023 Jul 20;10(8):ofad383. doi: 10.1093/ofid/ofad383. PMID: 37564743
207. DR Snyderman, LA McDermott, CM Thorpe, EJC Goldstein, AN Schuetz, S Johnson, DN Gerding, L Gluck, D Bourdas, KC Carroll, CK Lancaster, KW Garey, Q Wang, ST Walk, E. Duperchy. A US-Based National Surveillance Study for the Susceptibility and Epidemiology of *Clostridioides difficile* Isolates with Special Reference to Ridinilazole: 2020-2021. Antimicrob Agents Chemother 2023. e0034923. doi: 10.1128/aac.00349-23. PMID: 37728368
208. J Jo, C Hu, K Begum, W Wang, TM Le, S Agyapong, BM Hanson, H Ayele, C Lancaster, MJ Alam, AJ Gonzales-Luna, and KW Garey. Fecal Pharmacokinetics and Gut Microbiome Effects of Oral Omadacycline versus Vancomycin in Healthy Volunteers. J Infect Dis 2023 Dec 5;jiad537. doi: 10.1093/infdis/jiad537. PMID 38051631
209. Murphy BR, Dailey Barnes NJ, Hwang H, Peterson CB, Garey KW, Okhuysen P. Increased Prevalence of *Clostridioides difficile* Infection Among Pediatric Oncology Patients: Risk Factors for Infection and Complications. Pediatr Infect Dis J 2023 Dec 21. doi: 10.1097/INF.0000000000004178. PMID: 38134390 Lodise TP, Garey KW, Aram JA, Nathanson BH. Healthcare Resource Utilization and Discharge Readiness in Adult Hospitalized Patients With Candidemia or Invasive Candidiasis Who Received an Echinocandin: An Analysis of United States Hospitals. Open Forum Infect Dis 2024 Jan 3;11(1):ofad703. doi: 10.1093/ofid/ofad703. PMID: 38213636
210. Feuerstadt P, Allegretti JR, Dubberke ER, Guo A, Harvey A, Yang M, Garcia-Horton V, Fillbrunn M, Tillotson G, Bancke LL, LaPlante K, Garey KW, Khanna S. Efficacy and Health-Related Quality of Life Impact of Fecal Microbiota, Live-jslm: A Post Hoc Analysis of PUNCH CD3 Patients at First Recurrence of *Clostridioides difficile* Infection. Infect Dis Ther 2024 Jan 18. doi: 10.1007/s40121-023-00907-w. PMID: 38236515
211. Okhuysen PC, Ramesh MS, Louie T, Kiknadze N, Torre-Cisneros J, de Oliveira CM, Van Steenkiste C, Stychneuskaya A, Garey KW, Garcia-Diaz J, Li J, Duperchy E, Chang BY, Sukbuntherng J, Montoya JG, Styles L, Clow F, James D, Dubberke ER, Wilcox M. A Randomized, Double-Blind, Phase 3 Safety and Efficacy Study of Ridinilazole Versus Vancomycin for Treatment of *Clostridioides difficile* Infection: Clinical Outcomes With Microbiome and Metabolome Correlates of Response. Clin Infect Dis. 2024 Feb 2;ciad792. doi: 10.1093/cid/ciad792. PMID: 38305378
212. E Bassères, TA Eubank, K Begum, MJ Alam, J Jo, TM Le, CK Lancaster, AJ Gonzales-Luna, and KW Garey. Antibacterial activity of ibezapolstat against antimicrobial resistant clinical strains of *Clostridioides difficile*. Antimicrob Agents Chemother 2024 Feb 16:e0162123. doi: 10.1128/aac.01621-23. PMID. 38364016
213. Eubank TA, Dureja C, Garey KW, Hurdle JG, Gonzales-Luna AJ. Reduced Vancomycin Susceptibility in *Clostridioides difficile* is Associated with Lower Rates of Initial Cure and Sustained Clinical Response. Clin Infect Dis 2024;ciae087. doi: 10.1093/cid/ciae087. PMID: 38382090
214. C Hu, W Wang, J Jo, KW Garey. Development and validation of LC-MS/MS for quantifying omadacycline from stool for gut microbiome studies. J Chromatogr B Analyt Technol Biomed Life Sci 2024;1236:124057. doi: 10.1016/j.jchromb.2024.124057. PMID: 38447241
215. TA Eubank, C Hu, AJ Gonzales-Luna, KW Garey. Detectable Vancomycin Stool Concentrations in Hospitalized Patients with Diarrhea Given Intravenous Vancomycin. Pharmacoepidemiol Accepted Sept 26, 2023

216. TA Eubank, Ka Jantarathaneewat, J Jo, and KW Garey. Estimating *Clostridioides difficile* infection – associated readmission rates: A systematic review and meta-analysis. *Infect Contr Hosp Epidemiol*. 2024 May 27;1-5. doi: 10.1017/ice.2024.94. PMID: 38800851
217. TM Le, TA Eubank, A McKelvey, X Cao, JG Hurdle, KW Garey. Fidaxomicin resistance in *Clostridioides difficile*: a systematic review and predictive modeling with RNA polymerase binding sites. *Antimicrob Agents Chemother*. 2024 Nov 6:e0120624. doi: 10.1128/aac.01206-24. PMID: 39503488
218. TA Eubank, C Dureja, AJ Gonzales-Luna, JG Hurdle, KW Garey. Reduced vancomycin susceptibility in *Clostridioides difficile* is associated with specific ribotypes. *Open Forum Infect Dis* 2024 Oct 10;11(11):ofae588. doi: 10.1093/ofid/ofae588 PMID: 39512425
219. Begum K, Chua HC, Alam MJ, Garey KW, Jo J. A quantitative PCR to detect non-toxigenic *Clostridioides difficile*. *Microbiol Spectr*. 2024 Dec 11:e0160824. doi: 10.1128/spectrum.01608-24. PMID: 39660903.
220. J Jo, C Hu, TD Horvath, SJ Haidacher, K Begum, MJ Alam, and KW Garey. Phase I trial comparing bile acid and short-chain fatty acid alterations in stool collected from human subjects treated with omadacycline or vancomycin. *Antimicrob Agents Chemother* 2025:e0125124. doi: 10.1128/aac.01251-24. PMID: 39819014
221. HC Chua, TA Eubank, A Lee, K Rao, J Jo, KW Garey, and AJ Gonzales-Luna. Defining fulminant *Clostridioides difficile* infections: Assessing the utility of hypotension as a diagnostic criterion. *Open Forum Infect Dis* 2025;12(2):ofaf033. doi: 10.1093/ofid/ofaf033. PMID: 39896986
222. JK McPherson, JG Hurdle, ML Baker, T Hussain, A Kumar, KW Garey. The microbiome-restorative potential of ibezapolstat for the treatment of *Clostridioides difficile* infection is predicted through variant PolC-type DNA Polymerase III in Lachnospiraceae and Oscillospiraceae. *Antimicrob Agents Chemother* 2025:e0167924. doi: 10.1128/aac.01679-24. PMID 39982073
223. TM Wolfe, J Jo, NV Pinkham, ST Walk, and KW Garey. Microbiome impact of ibezapolstat and other *Clostridioides difficile* infection relevant antibiotics using humanized mice. *Antimicrob Agents Chemother* 2025:e0160424. doi: 10.1128/aac.01604-24. PMID 39998294
224. FS Midani, HA Danhof, N Mathew, CK Ardis, W Garey, JK Spinler, RA Britton. Emerging *Clostridioides difficile* ribotypes have divergent metabolic phenotypes. *mSystems* 2025:e0107524. doi: 10.1128/msystems.01075-24. PMID 40013784
225. TA Eubank, J Jo, MJ Alam, K Begum, JK McPherson, TM Le, TD Horvath, SJ Haidacher, EC Poggio, R Lin, C Seng Yue, MP Ducharme, G Koudssi, J Mercier, JD Alder, MH Silverman, and KW Garey for the Ibezapolstat Phase 2 Investigator Group. Efficacy, safety, pharmacokinetics, and associated microbiome changes of ibezapolstat compared with vancomycin in adults with *Clostridioides difficile* infection: a phase 2b, randomized, double-blind, active-controlled, multicenter study. *Lancet Microbe* 2025 Jun 11:101126. doi: 10.1016/j.lanmic.2025.101126. PMID 40516571
226. Jo J, Carlson TJ, Hu C, Williamson JC, Belin YT, Horvath TD, Haidacher SJ, Bassères E, Begum K, Alam MJ, and Garey KW. Fecal pharmacokinetics, microbiome, and bile acid changes in healthy subjects given intravenous followed by oral omadacycline; a phase 1 clinical trial. *J Antimicrob Chemother* 2025 Aug 12:dkaf278. doi: 10.1093/jac/dkaf278. PMID: 40796204

Case reports, Reviews, and Commentary

1. Garey KW. Crossbones: Calcium Channel Blockers. *Pharmacy Association of Western New York (P.A.W.N.Y.) Express Newsletter*, Sept 1996
2. Garey KW, Amsden GA, Johns CA. A possible interaction between butalbital and imipramine. *Pharmacotherapy* 1997;17(5):1041-2

3. Garey KW, Streetman DS, Rainisch MC. Azathioprine hypersensitivity reaction in an ulcerative colitis patient. *Ann Pharmacother* 1998;32(4):425-6
4. Garey KW, Rodvold KA. Antiretroviral Agents and Food Interactions. *Infect Med* 1998;15(12):836-9
5. Garey KW, Rodvold KA. Disulfiram Reactions and Anti-Infective Agents. *Infect Med* 1999;16(11):741-4
6. Garey KW, Amsden GW. Intravenous Azithromycin. *Ann Pharmacother* 1999;33(2):218-28
7. Garey KW, Amsden GW. Trovafloxacin: An Overview. *Pharmacotherapy* 1999;19(1):21-34
8. Bearden DT, Neuhauser MM, Garey KW. Telithromycin. A review of the first ketolide. *Pharmacotherapy* 2001 Oct;21(10):1204-22
9. Mutlu GM, Garey KW, Robbins RA, Danziger LH, Rubinstein I. Collection and analysis of exhaled breath condensate in humans. *Am J Respir Crit Care Med* 2001;164:731-737
10. C Kroegel, J Rödel, B Mock, KW Garey, and I Rubinstein. Chlamydia pneumoniae, Clarithromycin, and Severe Asthma. *Chest* 2001;120:1035-6
11. Gotfried M, Garey KW. Is asthma an infectious disease? *Clin Pulm Med* 2001;8(3):117-22
12. Garey KW and Gotfried MH. The role of virus and atypical bacteria in the pathogenesis of asthma. *Infect Dis Clin Pract* 2002;11:9-15
13. Chang K and Garey KW. Antibiotic Resistance in Community-acquired Uncomplicated Urinary Tract Infections. *Texas Pharmacy* 2002 Winter:22-5
14. KW Garey. The Role of Matching in Epidemiologic Studies. *Am J Pharm Educ* 2004;68(3):83-90
15. L Gerard, KW Garey, and HL DuPont. Rifaximin: A Non-Absorbable Rifamycin Antibiotic for Use in Non-Systemic Gastrointestinal Infections. *Exp Rev Anti-infect Ther* 2005;3(2):201-11
16. TP Lim, KW Garey, VH Tam. The evolution of pharmacokinetic-pharmacodynamic antimicrobial individualization / optimization strategies: where are we going and what problems do we still need to solve to make them bedside friendly? *Curr Infect Dis Report* 2008;10(1):9-13
17. KW Garey, M Salazar, D Shah, R Rodrigue, HL DuPont. A Review of Rifamycin Antibiotics for the Treatment of *Clostridium difficile*-associated diarrhea. *Ann Pharmacother* 2008;42(6):827-35
18. HL DuPont, K Garey, JP Caeiro, ZD Jiang. New Advances in *Clostridium difficile* Infection: Changing Epidemiology, Diagnosis, Treatment and Control. *Curr Opin Infect Dis* 2008;21:500-7
19. RF Yeh, KM Kuper, EA Coyle, KW Garey, JO Ikwuagwu, DO Maclayton, JF Mohr, WL Musick, SE Pass, E Rios, VH Tam, on behalf of the Houston Infectious Diseases Network. Significant Papers in Infectious Diseases Pharmacotherapy in 2007. *Amer J Health Systems Pharm* 2008;65(22):e72-e79
20. KK Birtcher, SM Corbett, SE Pass, EA Coyle, RF Yeh, J Tipton, KW Garey for the Academic Pharmacy Symposium. Defining the Academic Pharmacy Clinician: A report from a multi-institutional symposium. *Amer J Health Systems Pharm* 2010 Feb 1;67(3):231-8
21. RD Crutchley, J Miller, and KW Garey. Crofelemer, a novel agent for treatment of secretory diarrhea. *Ann Pharmacother* 2010;44(5):878-84
22. SS Ghantaji, K Sail, DR Lairson, HL DuPont, and KW Garey. Economic Healthcare Costs of *Clostridium difficile* Infection: A Systematic Review. *J Hosp Infect.* 2010;74(4):309-18
23. D Shah, MDQ Dang, R Hasbun, HL Koo, ZD Jiang, HL DuPont, and KW Garey. *Clostridium difficile* infection. An update on emerging antibiotic treatment options and antibiotic resistance. *Exp Rev Anti-infect Ther* 2010;8(5):555-64
24. J Cotreau, SF Baker, HL DuPont, and KW Garey. Rifaximin: a nonsystemic rifamycin antibiotic for gastrointestinal infections. *Exp Rev Anti-infect Ther* 2010 Jul;8(7):747-60.

25. HL Koo, KW Garey, HL DuPont. Future Novel Therapeutic Agents for *Clostridium difficile* Disease. *Exp Opin Investigat Drugs* 2010;19(7):1-12
26. Palmer HR, Cottreau JM, Garey KW, Hirsch EB, WL Musick, VH Tam, RF Yeh on behalf of the Houston Infectious Diseases Network. Significant Publications in Infectious Diseases Pharmacotherapy in 2009. *Amer J Health Syst Pharm* 2010;67(15):e34-e42.
27. DuPont HL and Garey KW. *Clostridium difficile* infection: an emerging epidemic with more questions than answers (Editorial). *Future Microbiology* 2010;5(8):1153-6
28. HR Palmer, J Weston, LO Gentry, M Salazar, K Putney, C Frost, JA Tipton, J Cottreau, VH Tam, KW Garey. Center for Antimicrobial Stewardship and Epidemiology (CASE): Improving patient care through clinical service, teaching, and research. *Amer J Health Syst Pharm* 2011;68:2170-4
29. J Cottreau, A Tucker, R Crutchley, and KW Garey. Crofelemer for the treatment of secretory diarrhea. *Expert Review of Gastroenterology and Hepatology* 2012;6(1):17-23
30. ND Beyda, RE Lewis, and KW Garey. Echinocandin Resistance in *Candida* species: Mechanisms of Reduced Susceptibility and Therapeutic Approaches. *Ann Pharmacother* 2012;46:1086-96
31. Arora V, Shah D, Garey K. Overview of *Clostridium difficile* infection as an emerging health care facility-acquired infection. *Hosp Pharm* 2013;48(2 Suppl 1):S1-S6
32. QM Yeo, R Crutchley, J Cottreau, A Tucker, and KW Garey. Crofelemer, a novel anti-secretory agent approved for the treatment of HIV-associated diarrhea. *Drugs Today (Barc)* 2013;49(4):239-85. PMID 23616951
33. ND Beyda, S Regen, RE Lewis, KW Garey. Immunomodulatory agents as adjunctive therapy for the treatment of resistant *Candida* species. *Curr Fung Infection Rep* 2013;7:119-25
34. Patel TS, Crutchley RD, Tucker AM, Cottreau J, Garey KW. Crofelemer for the treatment of chronic diarrhea in patients living with HIV/AIDS. *HIV/AIDS - Research and Palliative Care* 2013;5:153–162. PMID 23888120
35. MA Wanat and KW Garey. A Blueprint for Transitioning Pharmacy Residents Into Successful Clinical Faculty Members in Colleges and Schools of Pharmacy. *Amer J Pharm Educ* 2013;77(9):Article 200. PMID 24249862
36. Sayles C, Hickerson SC, Bhat RR, Hall J, Garey KW, Trivedi MV. Oral glutamine in preventing treatment-related mucositis in adult patients with cancer: A systematic review. *Nutr Clin Pract* 2016;31(2):171-9 PMID: 26507188
37. AK Sofjan, RJ Musgrove, KW Garey. Impact of new diagnostic approaches for invasive candidiasis on antifungal stewardship. *Curr Fungal Infect Rep* 2016 Apr 4: 1-10
38. Gorbach C, Blanton L, Lukawski B, Varkey AC, Pitman P, Garey KW. Benchmarking and medication error rates. *Am J Health Syst Pharm*. 2016 Jun 1;73(11):746. PMID: 27208057
39. Vickers R, Tillotson G, Goldstein EJC, Citron DM, Garey KW, Wilcox MH. Ridinilazole: a novel therapy for *Clostridium difficile* infection. *Int J Antimicrob Agents* 2016;48(2):137-43 PMID:27283730
40. T Rashid, H VonVille, I Hasan, KW Garey. Shoe soles as a potential vector for pathogen transmission: A systematic review. *J Appl Microbiol*. 2016; 121(5):1223-31. PMID: 27495010
41. T Rashid, H VonVille, I Hasan, KW Garey. Mechanisms for floor surfaces or environmental ground contamination to cause human infection: A systematic review. *Epidemiol Infect* 2016 Oct 26:1-11 PMID: 27780492
42. E Bassères, BT Endres, KM Dotson, MJ Alam, KW Garey. Novel antibiotics in development to treat *Clostridium difficile* infection. *Curr Opin Gastroenterol*. 2017 Jan;33(1):1-7. PMID: 28134686
43. BT Endres, E Bassères, MJ Alam, KW Garey. Cadazolid for the treatment of *Clostridium difficile*. *Expert Opinion on Investigational Drugs* 2017 Apr;26(4):509-514. PMID: 28286992

44. T. Carlson, BT Endres, E Basseres, A Gonzales-Luna KW Garey. *Ridinilazole for the treatment of C difficile infection*. Expert Opin Invest Drugs 2019;28(4):303-10. PMID: 30767587
45. C Dempsey, E Skoglund, KL Muldrew, KW Garey. Economic Healthcare Costs of Blood Culture Contamination: A Systematic Review. Amer J Infect Control 2019 Feb 19. pii: S0196-6553(18)31183-0. doi: 10.1016/j.ajic.2018.12.020. PMID:30795840
46. Vickers RJ, Bassetti M, Clancy CJ, Garey KW, Greenberg DE, Nguyen MH, Roblin D, Tillotson GS, Wilcox MH. Combating Resistance While Maintaining Innovation: The Future of Antimicrobial Stewardship. Future Microbiol. 2019 Sep 17. doi: 10.2217/fmb-2019-0227. PMID:31526186
47. Garey KW. Perils, pitfalls, and promise of primary prophylaxis for *Clostridioides difficile* infection (Editorial). Clin Infect Dis 2019 Sep 27. pii: ciz970. doi: 10.1093/cid/ciz970. PMID:31560048
48. G Doern, K Carroll, D Diekema, K Garey, M Rupp, M Weinstein, D Sexton. A Comprehensive Update on the Problem of Blood Culture Contamination and a Discussion of Methods for Addressing the Problem. Clin Microbiol Review 2019;33(1):e00009-19. PMID: 31666280
49. Carlson TJ, Blasingame D, Gonzales-Luna AJ, Alnezary F, and Garey KW. *Clostridioides difficile* ribotype 106: a systematic review of the antimicrobial susceptibility, genetics, and clinical outcomes of this common worldwide strain. Anaerobe. 2019 Dec 19;62:102142. doi: 10.1016/j.anaerobe.2019.102142. PMID:32007682
50. TJ Carlson, AJ Gonzales-Luna, KW Garey. Recent developments in antimicrobial therapy for gastrointestinal infections. Curr Opin Gastroenterol. 2020 Nov 21. doi: 10.1097/MOG.0696. PMID: 33229860
51. AJ Gonzales-Luna, TJ Carlson, KW Garey. Antibiotic therapies for *Clostridioides difficile* infection in children. J Pediatric Infect Dis Soc 2021 Nov 17;10(Suppl3):S52-S57. doi: 10.1093/jpids/piab059 PMID: 34791393
52. TA Eubank, AJ Gonzales-Luna, JG Hurdle, KW Garey. Genetic Mechanisms of Vancomycin Resistance in *Clostridioides difficile*: A Systematic Review. Antibiotics (Basel). 2022 Feb 16;11(2):258. doi: 10.3390/antibiotics11020258. PMID: 35203860
53. Garey KW, Rose W, Gunter K, Serio AW, Wilcox MH. Omadacycline and *Clostridioides difficile*: A Systematic Review of Preclinical and Clinical Evidence. Ann Pharmacother. 2022 Jun 3;10600280221089007. doi: 10.1177/10600280221089007. PMID: 35656828
54. Hu C, Garey KW. Nonmammalian models to study *Clostridioides difficile* infection; a systematic review. Anaerobe. 2023 Jan 7;102694. doi: 10.1016/j.anaerobe.2023.102694. PMID: 36626950
55. Gonzales-Luna AJ, Carlson TJ, Garey KW. Emerging Options for the Prevention and Management of *Clostridioides difficile* Infection. Drugs. 2023 doi: 10.1007/s40265-022-01832-x. PMID: 36645620
56. AJ Gonzales-Luna, TJ Carlson, KW Garey. Gut microbiota changes associated with *Clostridioides difficile* infection and its various treatment strategies. Gut Microbes 2023;15:1,2223345. PMID 37318134
57. AJ Gonzales-Luna, TJ Carlson, KW Garey. Review Article. Safety of live biotherapeutic products used for the prevention of *Clostridioides difficile* infection recurrence. Clin Infect Dis 2023 Dec 5;77(Supplement_6):S487-S496. PMID 38051970
58. Hu C, Garey KW. Microscopy methods for *Clostridioides difficile*.. Anaerobe. 2024 Feb 8;102822. doi: 10.1016/j.anaerobe.2024.102822. PMID: 38341023
59. Kuijper EJ, Garey KW. The new horizon of *Clostridioides difficile* infection treatment. Gastroenterol 2024 2024 Nov 4:S0016-5085(24)05658-0. doi: 10.1053/j.gastro.2024.10.032. PMID: 39505220
60. Fowler JF, Eubank TA, Garey KW. Proton pump inhibitor effect on macrophage and neutrophil function: a systematic review. Front Immunol 2024 Dec 24;15:1477993. doi: 10.3389/fimmu.2024.1477993. PMID: 39776898

61. A Shremo Msdi, A Haghparsat, KW Garey, EM Wang. Microbiome-based Therapeutics for Salt-sensitive Hypertension: A Scoping Review. *Nutrients* 2025;17(5):825. doi: 10.3390/nu17050825. PMID: 40077695
62. Smits WK, Garey KW, Riley TV, Johnson S. *Clostridioides difficile* is a Bacterial Priority Pathogen. *Anaerobe* 2025 doi: 10.1016/j.anaerobe.2025.102965. PMID: 40288746
63. Smits WK, Garey KW, Riley TV, Han YW, Young VB, Heritage J, Lillis CJ, Lyras D, Rupnik M, Johnson S. *Clostridioides difficile* should be considered a bacterial priority pathogen. *Lancet Microbe* 2025;101184. doi: 10.1016/j.lanmic.2025.101184. PMID: 40582366
64. A Shremo Msdi, EM Wang, KW Garey Prebiotics Improve Blood Pressure Control by Modulating Gut Microbiome Composition and Function: A Systematic Review and Meta-Analysis. *Nutrients* 2025 Jul 30;17(15):2502. doi: 10.3390/nu17152502. PMID: 40806090

Continuing Education Monographs

1. Garey KW, Amsden GW. Ciprofloxacin Bibliography 1991-98. Clinical Communication, Inc.
2. The Pharmacist's Role in Implementing National Guidelines for the Treatment of Community Acquired Pneumonia. ACPE #245-999-02-061-H01

RESEARCH GRANTS

Current Federal Research Support

NIH/NIAID R01 AI139261	Garey (MPI)	02/2023-02/2028
Decoding the clinical impact of the recent evolution of metronidazole resistance on <i>Clostridium difficile</i> infection		
NIH/NIAID 1P01AI152999-01	Garey (UH Site PI)	03/2021-03/2026
Dynamics of Colonization and Infection by Multidrug-resistant Pathogens in Immunocompromised and Critically Ill Patients (DYNAMITE)		
NIH/NIAID R44 AI136176-02	Garey (MPI)	07/2021-07/2026
A Serological Assay for Neutralizing Antitoxin Response in Patients with <i>Clostridioides difficile</i> Infection (Phase II)		
NIH/NIAID T32AI141349	Garey (UH Site PI)	07/01/2023-07/01/2025
TMC Training Program in AMR – Jacob McPherson		
NIH/NIAID T32AI141349	Garey (UH Site PI)	07/01/2025-07/01/2027
TMC Training Program in AMR – Thanh Phuong Le		
NIH/NIAID 1R03AI178015-01A1	Garey (PI)	02/01/2024-01/31/2026
Vancomycin Susceptibility Measures to Evaluate <i>C. difficile</i> infection Outcomes		

Past research support, Investigator initiated grants

Year	Project title Funding source	Amount	Role	Type
------	---------------------------------	--------	------	------

FEDERAL GRANTS

2012	Facilitating reporting of antimicrobial use to the National Healthcare Safety Network (NHSN) Centers for Disease Control and Prevention (CDC)	\$251,791	Co-PI
------	--	-----------	-------

2014	A clinical risk index for primary <i>Clostridium difficile</i> infection CDC via the Texas Dept of State Health Services	\$198,136	PI
2014	Community Household Environmental Studies on Potentially Pathogenic <i>Clostridium difficile</i> CDC via the Texas Dept of State Health Services	\$294,938	PI
2015	State-wide Assessment of Environmental <i>C. difficile</i> colonization CDC via Texas Dept of State Health Services	\$1,222,201	PI
2016	CRE and <i>C. difficile</i> surveillance CDC via Houston Health Department	\$280,274	PI
2016	Decoding antibiotic-induced susceptibility to <i>C. difficile</i> infection NIH/NIAID 1UO1 AI24290	\$660,671	MPI
2018	Relationships Between Heme Metabolism, Metronidazole Resistance and Treatment Failure in <i>Clostridium difficile</i> Infection NIH/NIAID 1R56AI126881-01A1	\$112,875	UH-PI
2019	The Genomics and Antagonism of Pathobiont Colonization NIH/NIAID U19 AI144297	\$112,987	UH-PI
2019	Decoding the clinical impact of the recent evolution of metronidazole resistance on <i>Clostridium difficile</i> infection NIH/NIAID R01 AI139261	\$573,750	UH-PI
2020	Ultrasensitive <i>C. difficile</i> toxin measurement for diagnosis and outcome prediction NIH/NIAID, R01 AI116596	\$186,832	UH-PI
2021	TMC Training Program in AMR – Taryn Eubank NIH/NIAID T32AI141349	\$126,783	UH-PI
2024	NLM Training Program in Biomedical Informatics – Thanh Le NIH/NLM 5 T15LM007093-31	UH-PI	

FOUNDATION GRANTS

2002	A Houston-Based Medicine Cabinet Cleanup Campaign National Association of Chain Drug Stores	\$2,000	PI	Foundation
2005	Type III Secretory Proteins and <i>Pseudomonas aeruginosa</i> Society of Infectious Diseases Pharmacists	\$15,000	PI	Foundation
2005	The Role of Type III Secretory Proteins and Inadequate Antimicrobial Therapy to Predict Mortality American Association of Colleges of Pharmacy	\$10,000	PI	Foundation
2007	Host cytokine polymorphism determinants for <i>Clostridium difficile</i> -associated diarrhea Society of Infectious Diseases Pharmacists	\$25,000	PI	Foundation
2010	A cell culture model system for evaluating biomarkers of severe <i>Clostridium difficile</i> disease Grants to Enhance and Advance Research	\$23,233	PI	State

FOR-PROFIT, INVESTIGATOR INITIATED GRANTS

2002	A 5-year Analysis of Antimicrobial Susceptibility Patterns and Hospital Demographics in Houston University of Houston New Investigator Grant	\$6,000	PI	State
2002	Clinical, Microbiological, and Economic Outcomes of ICU Patients with Invasive Fungal Infections: Merck	\$60,000	PI	For-profit
2003	Biofilm inhibition by clarithromycin for the prevention and treatment of infection Abbott	\$50,000	PI	For-profit
2004	Clinical and Economic Outcomes of Patients with Candidemia Merck	\$87,420	PI	For-profit
2004	Prevalence of AmpC in clinical strains of <i>P. aeruginosa</i> and its impact on clinical outcomes Astra Zeneca Pharmaceuticals	\$107,048	co-I	For-profit
2006	Activity of esomeprazole against nosocomial biofilm producing organisms Astra Zeneca Pharmaceuticals	\$75,000	PI	For-profit
2006	Long-term rifaximin therapy vs. comparators to prevent relapsing <i>Clostridium difficile</i> infection Salix	\$77,375	PI	For-profit
2006	Prevalence of AmpC in clinical strains of <i>Pseudomonas aeruginosa</i> and clinical outcomes Astra Zeneca Pharmaceuticals	\$97,420	co-I	For-profit
2007	Risk index to predict recurrent <i>Clostridium difficile</i> -associated diarrhea Viropharma	\$112,284	PI	For-profit
2007	Host inflammatory and immune response to <i>Clostridium difficile</i> -associated Diarrhea Roderick D. MacDonald Research Fund	\$50,000	PI	Foundation
2009	Clinical outcomes in candidemia patients based on in vitro susceptibility Merck	\$45,000	PI	For-profit
2010	Effectiveness and outcomes associated with a daptomycin PK/PD dose optimization protocol Cubist	\$77,750	PI	For-profit
2010	Susceptibility and recurrence of <i>Candida</i> species before and after a formulary change Merck	\$80,140	PI	For-profit
2011	A contemporary analysis of echinocandin use Merck	\$94,015	PI	For-profit
2011	Inhibition of Host Inflammatory Response of <i>C. difficile</i> toxins by Monoclonal antibodies Merck	\$76,010	PI	For-profit
2011	Direct Medical and Nonmedical Costs of Recurrent <i>Clostridium difficile</i> infection Merck	\$190,757	PI	For-profit
2012	Incidence and risk factors for breakthrough candidemia in hospitalized patients Astellas, Inc	\$87,750	PI	For-profit
2012	Protocol for the Collection and Handling of Whole Blood Specimens for T2Candida Assay T2 Biosystems	\$80,000	PI	For-profit

2012	Detecting Infections Rapidly and Easily for Candidemia Trial (DIRECT Study) T2 Biosystems	\$51,000	PI	For-profit
2012	Incidence, risk factors and outcomes associated with FKS mutants in patients with <i>C. glabrata</i> Astellas, Inc	\$115,532	PI	For-profit
2012	LOD comparison of Bactec vs Beta-7 T2 Biosystems	\$25,000	Co-PI	For-profit
2012	T2 Bacterial Assay Development: Protocol for the Collection of Whole Blood Specimens T2 Biosystems	\$40,000	PI	For-profit
2013	Development and validation of Clostridium difficile infection health-related quality of life instrument Merck	\$133,344	PI	For-profit
2013	Prospective Collection and Testing of Un-Spiked and Candida-Spiked Fresh Whole Blood T2 Biosystems	\$185,250	Co-PI	For-profit
2013	Pathomicrobiologic characteristics of <i>Clostridium difficile</i> recurrence Merck	\$79,177	PI	For-profit
2013	Impact of CB-183,315 exposure on in vitro inflammatory response Cubist	\$97,316	PI	For-profit
2013	Innate inflammatory response and immunopharmacologic activity against <i>Candida glabrata</i> Astellas, Inc	\$116,761	Co-PI	For-profit
2014	Humanistic Outcomes Associated with <i>Clostridium difficile</i> infection Cubist	\$127,345	PI	For-profit
2014	Detecting Infections Rapidly and Easily for Bacteremia Trial (DIREBT Study) T2 Biosystems	\$53,125	PI	For-profit
2014	Clinical Outcomes Associated with Pre-emptive Cytomegalovirus Therapy Merck & Co., Inc	\$158,115	PI	For-profit
2015	Antifungals on the Performance of the T2Candida Assay vs. Automated Blood Culture T2 Biosystems	\$24,531	Co-PI	For-profit
2015	Real-world Use of Crofelemer in HIV Patients on HAART Salix Pharmaceuticals	\$85,934	Co-I	For-profit
2015	Patterns of Healthcare Resource Utilization in Patients with C difficile infections Merck & Co.	\$120,743	PI	For-profit
2015	Accelerate System for Identification and Susceptibility of Gram-positive Bacteria Accelerate Diagnostics	\$60,787	PI	For-profit
2015	Collection and Handling of Stool Specimens for Techlab Assay Development TechLab, Inc	\$62,400	PI	For-profit
2015	Healthcare Resource Utilization in Patients with C difficile infections Merck & Co	\$113,651	PI	For-profit
2016	Environmental Contamination of Healthcare Associated Pathogens via Shoe Bottoms Healthysole	\$40,569	PI	For-profit

2016	How does fidaxomicin inhibit spore and toxin production; a mechanistic study Merck & Co.	\$123,514	PI	For-profit
2016	Defining the Unmet Medical Need of Novel Echinocandins; a Real-World Study Cidara Therapeutics, Inc	\$65,232	PI	For-profit
2016	SMT19969 Inhibition toxin production and cell division Summit Pharmaceuticals	\$88,123	PI	For-profit
2018	<i>In vitro</i> and pharmacologic properties of eravacycline against <i>C. difficile</i> Tetraphase Pharmaceuticals	\$94,021	PI	For-profit
2018	<i>In vitro</i> and pharmacologic properties of omadacycline against <i>C. difficile</i> Paratek Pharmaceuticals	\$94,021	PI	For-profit
2018	Phase I Microbiome Studies of ACX-362E Acurx Pharmaceuticals	\$278,829	PI	For-profit
2019	Effect of ibezapolstat on <i>C. difficile</i> spores and toxins Acurx Pharmaceuticals	\$120,756	PI	For-profit
2020	Microbiome studies of omadacycline Paratek Pharmaceuticals	\$204,725	PI	For-profit
2020	Ridinilazole mechanism of action Summit Pharmaceuticals	\$146,250	PI	For-profit
2021	Phase 2 studies of ibezapolstat Acurx Pharmaceuticals	\$249,987	PI	For-profit

Contracts / Industry-sponsored trials

Year	Project title Funding source	Amount	Role	Type
2004	Collaborative Exchange of Antifungal Research (CLEARII) Enzon pharmaceuticals	\$90,000	PI	For-profit
2014	A randomized, double-blind, active controlled study of CB-183,315 Cubist Pharmaceuticals	\$83,076		

Sponsored Fellowships / Residencies / Minisabbatical:

Year	Title Sponsor	Amount
2005	Minority Undergraduate Research Fellow (MURF) American Society of Microbiology	\$3,500
2005	Summer Undergraduate Research Fellow (SURF) University of Houston Honors College	\$2,850
2005	Clinical Pharmacy Minisabbatical Program American College of Clinical Pharmacy (ACCP)	\$2,750

2009	Infectious Diseases Specialty Residency Society of Infectious Diseases Pharmacists	\$40,000
2011	Infectious Diseases Specialty Residency Society of Infectious Diseases Pharmacists	\$40,000

Awarded Educational Grants

Pfizer Pharmaceuticals (2001)	\$2,500
Ortho-McNeil Pharmaceuticals (2002)	\$5,000
Cardinal Health Pharmacy Provider Services (2004)	\$10,000
Viropharma, Inc (2006)	\$5,000
Viropharma, Inc (2007)	\$5,000
Viropharma, Inc (2008)	\$5,000
Viropharma, Inc (2009)	\$5,000
Salix Pharmaceuticals (2008)	\$5,000
Salix Pharmaceuticals (2009)	\$5,000

GRANT PROPOSAL REVIEWER

NIH NIAID special emphasis panel ZAI1-AWA-M-C1 2023

INVITED NATIONAL / INTERNATIONAL PRESENTATIONS

2002

- Current Issue and Trends in Gram Positive Bacterial Infections. Infectious Disease Pharmacotherapy Symposium, Lee Garden Plaza Hotel, Hat-Yai, Songkla, Thailand. March 26-28 2002
- Handheld devices/PDAs: The future of pharmacy documentation. 54th Annual Meeting of the Texas Society of Health System Pharmacists (TSHP), Galveston, TX. April 15, 2002

2003

- Immunomodulatory effects of macrolides. University of Houston College of Pharmacy Infectious Disease Pharmacotherapy Symposium 2003, Houston, TX. May 30, 2003
- Pharmacoepidemiology: A Primer. 2003 Annual Meeting of the American College of Clinical Pharmacy, Atlanta, GA. November 2-5, 2003

2004

- Trends in Infectious Disease Pharmacotherapy. Lee Garden Plaza Hotel, Hat-Yai, Songkla, Thailand. March 22-26, 2004
- Improving Precepting Skills. Texas Society of Health-System Pharmacists 56th Annual Meeting. Houston, TX. April 16, 2004
- Common Challenges in Clinical Trial Data Interpretation: A Panel Discussion. 2004 Annual Meeting of the American College of Clinical Pharmacy. Dallas, TX. October 24-27, 2004.
- Overview of surgical site infections and prevention strategies. Gulf Coast Society of Health System Pharmacists Annual Meeting, Houston, TX. November 6, 2004
- Treatment of Methicillin-resistant *Staphylococcus aureus* infections: Old & Reliable versus New & Improved. 2004 ASHP Midyear Clinical Meeting. Orlando, FL. December 8, 2004

2005

- Antibiotic Surgical Prophylaxis: Timing is Everything. 2005 ASHP Midyear Clinical Meeting. Las Vegas, NV. December 6, 2005

2006

- Infectious Disease. 58th Annual Meeting of the Texas Society of Health System Pharmacists (TSHP), Galveston, TX. April 2, 2006

- Infectious disease update and Bacterial resistance. Infectious Disease Pharmacotherapy Symposium, Lee Garden Plaza Hotel, Hat-Yai, Songkla, Thailand. May 1-5 2006
 - Methicillin-resistant *S. aureus*. A treatment option debate. American College of Clinical Pharmacy New York State Chapter Annual Meeting. Albany, NY. October 6, 2006
 - Hot Topics in Infectious Diseases (Co-moderator and presenter): Hypervirulent *Clostridium difficile*. 2006 ASHP Midyear Clinical Meeting. Anaheim, CA. December 7, 2006
- 2007**
- An update on *Clostridium difficile*. Arizona Pharmacy Alliance Health Systems Academy Conference. Phoenix, AZ. April 14, 2007
 - In case you missed it: Top Ten Papers in Medicine, 2007 (Moderator and presenter). ASHP Midyear Clinical Meeting. Las Vegas, NV. December 5, 2007
 - Debates in Therapeutics: Should vancomycin be considered first line therapy for *Clostridium difficile* infections? ASHP Midyear Clinical Meeting. Las Vegas, NV. December 5, 2007
- 2008**
- Prevention and Treatment Strategies for *Clostridium difficile*-associated Diarrhea. Society of Critical Care Medicine Pharmacotherapy in Critical Illness, Philadelphia, PA. March 28-29, 2008
 - Update on Treatment of Fungal Infections in the Critically Ill Patient. Society of Critical Care Medicine Pharmacotherapy in Critical Illness, Philadelphia, PA. March 28-29, 2008
 - Optimal empiric therapy for candidemia. 5th Annual Critical Care Pharmacotherapy Symposium Boston. MA April 4th 2008
 - Top Ten Papers in Infectious Diseases. 32nd Annual Symposium on Rational Therapeutics: A Seminar in General Medicine. Anaheim, CA. July 13, 2008
 - Why You Buggin? ID Update for the Frontline Pharmacist. ASHP's Great eXpectations Conference for New Practitioners 2008. New York, NY. August 22-24, 2008
 - In case you missed it: Top Papers in Medicine, 2008 (Moderator and presenter). ASHP Midyear Clinical Meeting. Orlando, FL. December 10, 2008
- 2009**
- Bugs vs. Drugs: Infectious Disease Update. APhA Annual Meeting. San Antonio, TX. April 3, 2009
 - *C. difficile* update. University of Houston College of Pharmacy Infectious Disease Pharmacotherapy Symposium 2009, Houston, TX. May 1, 2009
 - Don't Bug Me! Ramping Up an Antimicrobial Stewardship Program (Moderator and presenter). ASHP Summer Meeting. Rosemont, IL. June 14-17, 2009
 - Clinical Update for Managers (Moderator). ASHP Summer Meeting. Rosemont, IL. June 14-17, 2009
 - Most Influential Publications in Infectious Diseases Pharmacotherapy, 2008-2009. 49th ICAAC. San Francisco, CA. September 11 2009
 - Keeping up with the Guidelines: Infectious Diseases Guidelines (Moderator and presenter). ASHP Midyear Clinical Meeting, Las Vegas NV. Dec 8, 2009
 - In case you missed it: Top Papers in Medicine, 2009 (Moderator and presenter). ASHP Midyear Clinical Meeting, Las Vegas NV. Dec 8, 2009
- 2010**
- Germ nation: Infectious Disease Update. APhA Annual Meeting. Washington, DC. March 14, 2010
 - Infectious Diseases Update in Texas: From Bench to Bedside to Beyond (Moderator and presenter). 62th Annual Meeting of the Texas Society of Health System Pharmacists (TSHP), Galveston, TX. April 9, 2010
 - Germ Nation: Infectious Disease Update 2010 (Encore), APhA Live. Memphis, TN. October 16, 2010
- 2011**
- Preventing Health Care-Associated Infections. APhA Annual Meeting. Seattle, WA March 28, 2011
 - Update on Fidaxomycin. Annual Meeting of the Society of Infectious Diseases Pharmacist. Chicago, IL September 16, 2011

- Guideline and Literature Update in Infectious Diseases 2011 (Moderator and Presenter). ASHP Midyear Clinical Meeting, New Orleans LA. Dec 7, 2011

2012

- Infectious Diseases Update 2012. APhA Annual Meeting. New Orleans, LA. March 11, 2011
- Fidaxomicin and its place in the management of *C. difficile* infection. Greater New York Hospital Association. Webinar. Mar 14, 2012
- Using Antimicrobial Stewardship Programs to Optimize the Use of New Anti-infectives. ASHP Advantage Seminar Series. Presented at the Annual meetings of:
 - Virginia Society of Health Systems Pharmacists, Wintergreen, VA. April 20, 2012
 - Louisiana Society of Health-Systems Pharmacists, New Orleans, LA May 26, 2012
 - Idaho Society of Health-Systems Pharmacists, Sun Valley, ID Sept 30, 2012
 - New Hampshire Society of Health-Systems Pharmacists, Concord, NH Oct 8, 2012
 - Georgia Society of Health-Systems Pharmacists, Young Harris, GA Oct 19, 2012
- Surgical Prophylaxis: Dosage Recommendations, Tissue Penetration, and Pharmacokinetic Considerations. 52nd ICAAC. San Francisco, CA Sept 10, 2012
- Alternative treatments for *Clostridium difficile* associated diarrhea. ACCP Annual Meeting, Hollywood, FL Oct 22, 2012
- *Clostridium difficile* infection: New drugs and new strategies. ASHP Midyear Clinical Meeting, Las Vegas NV. Dec 4, 2012

2013

- Infectious Diseases Update 2013. APhA Annual Meeting. Los Angeles, CA. March 3, 2013
- What's the Poop on *Clostridium difficile* Infection in 2013. MAD-ID 2013 Annual Meeting. Orlando, FL May 9, 2013
- The Role of Laboratory Testing in Managing Fungal Infections. MAD-ID 2013 Annual Meeting. Orlando, FL May 11, 2013
- Trans-Atlantic Task Force on Antimicrobial Resistance (TATFAR). European Center for Disease Prevention and Control (ECDC). Stockholm, Sweden June 17-19, 2013
- Mentoring pharmacy residents to successful clinical faculty. AACP Annual Meeting. Chicago, IL July 15, 2013
- Appropriate dosing of antifungals. Trends in Medical Mycology (TIMM). Copenhagen, Denmark. October 12, 2013
- Update on *C. difficile*. ASHP Midyear Meeting. Orlando, Florida. December 11, 2013

2014

- Update in Infectious Diseases. ASHP Annual Meeting. Las Vegas, NV. June 1, 2014
- New treatment strategies for *C. difficile*. Anaerobe 2014 Congress. Chicago, IL July 1, 2014
- Antibiotic management – Is it time to think differently with *Clostridium difficile*. ICAAC Workshop, September 5, 2014. Washington, DC
- Management of Invasive Fungal Infections: Applying Evidence-based Strategies and Individualizing Antifungal Therapy. ASHP Midyear December 10, 2014. Anaheim, CA

2015

- Tips for a successful research career. Temple University School of Pharmacy Research Day. February 20, 2015. Philadelphia, PA
- *Clostridium difficile*. Ongoing research and implications for best practice. Texas Healthcare Safety Conference. August 21, 2015. Bay City, TX
- Updates in the treatment of *C. difficile*. ID-Week 2015. October 10, 2015. San Diego, CA
- Updates in the treatment of *C. difficile*. ASHP Midyear Clinical Meeting 2015. December 10, 2015. New Orleans, LA

2016

- Key Considerations for Improving Patient Outcomes with Antimicrobial Stewardship Programs. Idaho Society of Health Systems Pharmacists Annual meeting. March 6, 2016. Boise ID; Encore

presentations: West Virginia Society of Health System Pharmacist. April 1, 2016 and Montana Society of Health System Pharmacists. April 30, 2016

- Antimicrobial stewardship. Vancouver Island Healthcare System Grand Rounds, Victoria, BC Canada. September 14, 2016
- Update on New Antibiotics. New Mexico Society of Health Systems Pharmacists Annual Meeting. October 3, 2016
- Environmental evaluation of *C. difficile*. APIC Austin Chapter annual meeting. Austin, TX October 20, 2016
- Update on *C. difficile*; New Drugs and new bugs. UT Tyler Health Science Center Grand Rounds, Tyler, Texas November 18, 2016
- Making Antimicrobial Stewardship a Priority: Integrating Evidence-based Practices and Guidelines to Improve Antimicrobial Use. 2016 ASHP Annual Midyear Clinical Meeting. Las Vegas, NV Dec 7, 2016

2017

- Consequences of recurrent CDI on Patients & Healthcare facilities. 22nd Congress of the European Association of Hospital Pharmacists, Cannes France March 23, 2017
- Translational research involving *Clostridium difficile*: Blending the host and the bug. Montana State University Frank M. Nelson Distinguished Lecture Series, March 28, 2017
- Tips for a Successful Pharmacy Career. West Virginia University Rho Chi Bergy Lecture, Morgantown, WV, April 9, 2017
- Antibiotic-related Changes in the Microbiome and *Clostridium difficile* infection. Making a Difference in Infectious Diseases (MAD-ID), Orlando, FL May 11, 2017
- Texas-wide Surveillance of *Clostridium difficile*. Alliance of Professional in Infection Control TX Annual meeting, Temple TX. Oct 9, 2017.
- A strawberry-flavored pearl for *Clostridium difficile* infection. ASHP Clinical Meeting 2017, Orlando, FL Dec 6, 2017.

2018

- An update on *C. difficile* Infection: The guidelines have arrived. Oregon Health Science University Grand Rounds, Portland, OR. March 13, 2018
- New updates on *C. difficile* infection. UTMB Pathology Grand Rounds, Galveston, TX April 16, 2018
- An update on the *C. difficile* guidelines and fecal microbiota transplantation. ASHP NY Chapter (webinar). May 1, 2018
- Early emergence of epidemic *Clostridioides difficile* ribotype 027 lineages in the US. NIH U01 Systems Biology meeting, La Jolla, CA Sept 14, 2018
- Group Leader, ID-Week 2018 Poster Board Session: *C. difficile*. San Francisco, CA Oct 4, 2018
- Best Practice Update on *C. difficile*. ASHP Clinical Meeting 2018, Anaheim, CA Dec 3, 2018.

2019

- An integrated curriculum to prepare pharmacy students at the University of Houston. 139th Annual Meeting of the Pharmaceutical Society of Japan. Chiba, Japan. March 20, 2019
- *C. difficile* infection. Improving provider-patient communication to hasten diagnosis and treatment. Osteopathic Physicians and Surgeons of California Society 30th Annual Fall Conference. Monterey, CA Sept 22, 2019. Encore presentations: Maryland State meeting, Gaithersburg MD, Oct 6, 2019 and Arizona State meeting, Tucson, AZ Nov 3, 2019
- One Health Perspective on Healthcare Acquired Infections. Grand Rounds, University of Tennessee Health Science Center, Memphis TN Nov 7, 2019
- Strategies for Prevention and Treatment of Recurrent *C. difficile* Infection. 2019 ASHP Midyear Clinical Meeting, Las Vegas, NV Dec 9, 2019
- Recognizing, treating, and preventing recurrence of *Clostridium difficile* infection in patients with IBD. 2019 Annual AIBD Conference, Orlando, FL Dec 14, 2019

2020

- An update on C diff diagnostics. 3rd Annual Center for Antimicrobial Resistance and Microbial Genomics (CARMiG) Annual meeting. Houston, TX Jan 24, 2020
- Early functional metagenomics changes associated with the novel antibiotic, Ibezapolstat. Anaerobe 2020 Biannual meeting, Virtual. Jul 23, 2020
- Importance of fecal microbiota transplantation vs. pharmacotherapy in the treatment of C diff infection (Debate style). IDWeek 2020. Virtual Oct 23, 2020

2021

- *C. difficile* diagnosis and treatment. Grand Rounds. Duke Medical School Division of Infectious Disease (virtual). April 12, 2021
- An update on *C. difficile* infection. Grand Rounds. Houston Methodist Hospital (virtual). May 4th, 2021

2022

- *C. difficile* infection. 5th Annual Center for Antimicrobial Resistance and Microbial Genomics (CARMiG) Annual meeting. Houston, TX Jan 23, 2022
- Return of the MDROs: Focus on *C. difficile* infection. Texas Healthcare Safety Conference (virtual). May 19, 2022
- Past, Present, and Future of *C. difficile* infection. 24th Annual MAD-ID, Orlando, FL May 20, 2022
- The Gut Microbiome and its Role in Drug Metabolism. 2022 ACCP Global Conference on Clinical Pharmacy. San Francisco, CA Oct 15, 2022

2023

- Advancing Patient Care in Pharmacy: If you can dream it, you can do it. Keynote Address, Texas Society of Health Systems Pharmacists Annual Meeting. Galveston, TX April 21, 2023
- New Horizons and Expert Insights on the Management of Recurrent *Clostridioides difficile* Infection. Digestive Diseases Week 2023. Chicago, IL May 6, 2023

2024

- Efficacy, formulary, and implementation of LBPs. 26th Annual MAD-ID, Orlando, FL May 11, 2024
- An update on C diff infection. Texas ID Society Meeting. Austin, TX June 11, 2024
- Ibezapolstat Clinical Development Update. International *C. difficile* symposium (ICDS). Bled, Slovenia. Sept 17, 2024
- Microbiome changes associated with intravenous omadacycline (oral presentation). ID Week 2024. Los Angeles, CA. Oct 18, 2024